Dear APSARD Colleagues:

It is my pleasure to welcome you to the 2018 Meeting of the American Professional Society of ADHD and Related Disorders! APSARD is the premier, multidisciplinary organization devoted to the advancement of both the science and clinical practices benefitting individuals with ADHD throughout the lifespan. This year’s program is enriched with state of the art plenaries, symposia addressing key issues, posters, and networking opportunities with prominent investigators, clinicians, and colleagues from around the globe who all come to APSARD.

Despite increased awareness of ADHD in all age groups, huge educational gaps remain among primary and specialty care providers, and there is limited access to evidence-based treatments, especially in adults. We need your help in broadening the reach of APSARD and achieving our scientific and educational goals.

Please introduce yourself to any board member or officer if you have suggestions or feedback, and ask about volunteering for APSARD committees. We also hope you will participate in our educational activities throughout the year, refer colleagues for membership, and become more involved through the year.

I know you will enjoy the meeting and interacting with your APSARD colleagues.

With warm regards,

Mark Stein, Ph.D., ABPP
APSARD President
Welcome to the APSARD Annual Meeting

On behalf of the APSARD Annual Meeting Program Committee, we are delighted to welcome you to the 2018 APSARD Annual Meeting.

The conference features nationally and internationally renowned faculty who present recent research findings relevant to clinical practice. If you are new to APSARD and/or the annual meeting, I would like to highlight that APSARD takes great pride in recruiting faculty from the US and abroad who are pre-eminent in the ADHD field, and offering presentations that represent cutting edge science in a manner that is accessible to and informative for clinicians and clinician-researchers. A summary of the schedule is presented below. To me, all sessions are highlights!

- **Friday, January 12**
  - Opening Plenary, ADHD and Cognition
  - Welcome Reception

- **Saturday, January 13**
  - Breakfast for Travel Awardees
  - President’s Summary
  - Plenary Session: New Data on Treatment of ADHD and Impairments in Adulthood
  - Poster Presentations at lunch – Including a Data Blitz Session
  - Symposium Sessions on ADHD and Technology: The Opportunities and Perils and Outside the Pill Bottle: Assessment and Management of Adult ADHD.
  - Lifetime Achievement Award Plenary: Joseph Sergeant, Ph.D.
  - Meet the Experts Sessions (Pharmacotherapy; Psychosocial Intervention)
  - Reception: with Faculty and Attendees

- **Sunday, January 14**
  - APSARD Business Meeting
  - Plenary Sessions, Genetic and Environmental Factors in ADHD and ADHD As a Brain Disorder: Why is This So Difficult to Establish?
  - Lunch Discussion Groups on International Perspectives of ADHD and ADHD in the Prison System.
  - Symposia Sessions: New Perspectives on ADHD and Mood Dysregulation and Coaching as an Intervention for Adults with ADHD: What Does the Evidence Tell Us and What Constitute Best Practices?

Organization

- The meeting is sponsored by the American Society for ADHD and Related Disorders (APSARD).
  - The Program Committee develops program content and invites speakers, evaluates submitted proposals.
- Parthenon Management Group organizes the APSARD Annual Meeting.

The APSARD Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Most importantly, please join us and become a member if you are not already!

Best Regards,

Jeffrey Newcorn, M.D.
Icahn School of Medicine at Mount Sinai
Get Connected…

Download the mobile app for the 2018 APSARD Annual Meeting

Search ‘APSARD2018’ in the App Store for iPhones and Google Play Store for Androids today!

The mobile app is a tool that will allow you to browse the Annual Meeting schedule, view abstracts, and plan your agenda for the meeting.

- Tap the Program icon to search the schedule by date and time. Tapping a session will show additional information such as speakers and abstracts.
- Use the Attendees icon to view the APSARD attendee list.
- Tap the Info icon to view helpful documents such as a dining guide with info on area restaurants or a list of presenter disclosures.
- The Facebook and Twitter icons will connect you directly to APSARD social media.
- Logging in to the app will allow you to ‘pin’ sessions to your schedule that can be uploaded to your phone calendar.

Don’t forget to follow us on social media!

@APSARD

APSARD WiFi:
WiFi Network: Marriott_CONFERENCE
conference code: apsard2018
## TABLE OF CONTENTS

Meetings Space Maps ........................................... 5
Award Winners and Featured Speakers ......................... 7
Acknowledgements .................................................. 23
Meeting Announcements .......................................... 25
Friday, January 12, 2018 ............................................ 31
Saturday, January 13, 2018 ......................................... 35
Sunday, January 14, 2018 ............................................ 45
Posters .................................................................. 55
Author Index ............................................................. 69
Notes .................................................................. 73

Disclosures for all APSARD presenters can be viewed at www.APSARD.org
Award Winners and Featured Speakers

Lifetime Achievement Award

Joseph Sergeant, Ph.D.
Vrije Universiteit

Professor Joseph Sergeant began his research on the attentional problems of hyperactive children in 1975 in Groningen, The Netherlands and from 1985 he was Professor and Chair of Clinical Psychology at the University of Amsterdam. In 1999, he moved to the Vrije Universiteit, Amsterdam to set-up a new department of Clinical Neuropsychology in which he was Professor and chair. In this period, Professor Sergeant set-up with colleagues one of the largest Adult ADHD neuropsychological projects, which included evaluation with neuropsychological measures the effect of treatment to adult ADHD patients. He is currently emeritus Professor of Clinical Neuropsychology.

In 1987 he founded the European Network on Hyperkinetic Disorders (Eunethydis), which has developed as a key training network for child psychiatrists, neurologists and psychologists. Professor Sergeant handed over the chairmanship of Eunethydis to Professor Tobias Banaschewski January 1st 2015. Under Professor Sergeant’s chairmanship, Eunethydis was expanded to take into account the emerging issue of adult ADHD.

Eunethydis has a workgroup: European ADHD Guidelines Group (EAGG) of which Professor Sergeant is chair. EAGG has produced three sets of Guidelines for the treatment of ADHD and a recent meta-analysis of Non-pharmacological interventions in ADHD. An important task for the EAGG in recent years has been to indicate interventions suitable for adult ADHD. Professor Emily Simonoff succeed him as Coordinator of the EAGG January 1st, 2015.

Professor Sergeant has published over 250 articles in scientific journals.

Professor Sergeant was in 2010 knighted by the Queen of The Netherlands and is Officer and Knight in the Order of Oranje Nassau for his contribution to the research and treatment of ADHD individuals.
Recipient of the Best Paper in the
Journal of Attention Disorders Award

*Is Maternal Smoking During Pregnancy a Risk Factor for Cigarette Smoking in Offspring? A Longitudinal Controlled Study of ADHD Children Grown Up*

Joseph Biederman, Mary Kate Martelon, K. Yvonne Woodworth, Thomas J. Spencer, and Stephen V. Faraone

**Joseph Biederman, M.D.**
Massachusetts General Hospital

Dr. Biederman is Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital, Director of the Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorders at the Massachusetts General Hospital, and Professor of Psychiatry at the Harvard Medical School. Dr. Biederman has been a mentor to more than 15 junior investigators in the field. He is on the editorial board of multiple journals, a reviewer for many Psychiatric journals, and has served as a grant reviewer in the Child Psychopathology and Treatment Review Committee of the NIMH. Dr. Biederman is the author and co-author over 800 scientific articles, 650 scientific abstracts, and 70 book chapters. Dr. Biederman is Board Certified in General and Child Psychiatry.
### AWARD WINNERS & FEATURED SPEAKERS

#### Travel Grant Awardees

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Venkat Bhat, M.D.</strong></td>
<td>University of Toronto</td>
</tr>
<tr>
<td><strong>Natalie Miller, Ph.D.</strong></td>
<td>University of Maryland - College Park</td>
</tr>
<tr>
<td><strong>Mariely Hernandez, M.A.</strong></td>
<td>The City College of New York/ CUNY Graduate Center</td>
</tr>
<tr>
<td><strong>Prerona Mukherjee, Ph.D.</strong></td>
<td>MIND Institute, University of California Davis School of Medicine</td>
</tr>
<tr>
<td><strong>Lisa Jacobs, M.B.A., M.D.</strong></td>
<td>Stanford Psychiatry</td>
</tr>
<tr>
<td><strong>Luke Norman, Ph.D.</strong></td>
<td>University of Michigan</td>
</tr>
<tr>
<td><strong>Traci Kennedy, Ph.D.</strong></td>
<td>University of Pittsburgh</td>
</tr>
<tr>
<td><strong>Jameson Patak, B.S.</strong></td>
<td>SUNY Upstate Medical University</td>
</tr>
</tbody>
</table>
Featured Speakers

Friday, January 12, 2018 from 5:30 PM – 7:30 PM
ADHD and the Wandering Mind: A New Perspective on Inattention in ADHD

Phil Asherson, MBBS, MRCPsych, Ph.D.
King’s College London

Philip Asherson is Professor of Molecular and Clinical Psychiatry working in the department of Social Genetic and Developmental Psychiatry (SGDP) at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London. He completed his Ph.D. on molecular genetic studies of schizophrenia before joining the SGDP in 1996 when he worked with Professor Eric Taylor. He was among the first senior consultants in the UK to specialize in the diagnosis and treatment of ADHD in adults. Since 1996 he has developed a program of research on clinical, quantitative and molecular genetics of ADHD, with a focus on adults with ADHD. Recent work identified a key role of mood lability in ADHD and he is extending his studies on ADHD to populations in which emotional instability is common. He currently leads a project investigating the effects of methylphenidate on ADHD, aggression and behaviour in young adult offenders with ADHD. He also leads a group investigating clinical, cognitive and neural biomarkers of mind wandering, and their relationship to ADHD and the treatment response to pharmacological and non-pharmacological interventions. He is a member of the guideline development group for the National Institute of Health and Clinical Excellence (NICE) and recently received a Senior Investigator Award for the National Institute of Health Research in the UK.
AWARD WINNERS & FEATURED SPEAKERS

Friday, January 12, 2018 from 5:30 PM – 7:30 PM
So We Find Cognitive Deficits in ADHD: Big Deal? Where Does This Lead Us?

Trevor Robbins, C.B.E., FRS, Ph.D.
University of Cambridge

Trevor is Professor of Cognitive Neuroscience, being elected to the Chair of Expt. Psychology (and Head of Department until 2017) at the University of Cambridge, from October 2002. He has been based in Cambridge for most of his scientific career, receiving his Ph.D. there in 1975. He is a Fellow of the British Psychological Society (1990), the Academy of Medical Sciences (2000), and the Royal Society (2005) the most prestigious science society in the U.K. He has published about 800 full papers, with an H index of about 173. He has co-edited eight books, most recently Translational Neuropsychopharmacology (Springer, 2016). He edits Psychopharmacology (since 1980) and Current Opinion in the Behavioral Sciences and is an editorial advisor for Science.

Trevor directs the ‘Behavioural and Clinical Neuroscience Institute’ (BCNI) (founded in 2005 with funding from the MRC and Wellcome Trust) the mission of which is to enhance translation from basic to clinical neuroscience with particular reference to impulsive-compulsive disorders including drug addiction. His interest in translation began with his co-invention in 1987 of the CANTAB computerized neuropsychological battery, which is currently used in over 700 institutes and clinical centers world-wide.

He received the Distinguished Scientific Contribution Award for 2011 from the American Psychological Association. He was made a CBE in the New Year’s Honours list of the U.K. in 2012 “for services to medical research”. In 2014 he shared the ‘Brain Prize’ of the Grete Lundbeck European Brain Research Foundation, the most valuable in neuroscience, for his work on human mental disorders. In 2015 he received the “Lifetime Achievement Award” of the British Association for Psychopharmacology’. In 2016, he received the Robert Sommer Award for research into schizophrenia. In 2017 received the Gold Medal of the Society for Biological Psychiatry (USA) work on cortico-striatal systems and their modulation, and, most recently, the Patricia Goldman-Rakic Award in Cognitive Neuroscience.
AWARD WINNERS & FEATURED SPEAKERS

Friday, January 12, 2018 from 5:30 PM – 7:30 PM

Is ADHD a Disorder of Cognition?

Anthony Grace, Ph.D.
University of Pittsburgh

Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA. He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral training with Dr. Rodolfo Llinas in the Department of Physiology and Biophysics at New York University School of Medicine. Dr. Grace has been involved in translational research related to the dopamine system for over 30 years. His early work pioneered the mode of action of antipsychotic drugs, and the identification and characterization of dopamine-containing neurons, and was the first to provide a means to quantify their activity state and pattern in a way that is the standard in the literature. His current work involves novel treatments for schizophrenia and its prevention, the role of dopamine in anhedonia and affective disorders, and the mode of action of ketamine and novel antidepressant drugs. Dr. Grace has received several awards for his research, including the William K. Warren Award for Excellence in Schizophrenia Research, the Paul Janssen Schizophrenia Research Award and the Lilly Basic Scientist Award from the International College of Neuropsychopharmacology, the Efron Award and the Axelrod Award from the American College of Neuropsychopharmacology, the Gold Medal award from the Society of Biological Psychiatry, the Outstanding Basic Research award from the Schizophrenia International Research Society, as well as a NIMH MERIT award, a Distinguished Investigator award from the National Alliance for Research in Schizophrenia and Depression, the Judith Silver Memorial Investigator Award from the National Alliance for the Mentally Ill, a Fellow of the American Association for the Advancement of Science, and appointment as a Distinguished Professor of Neuroscience at the University of Pittsburgh. He is also a past member of the governing council of the American College of Neuropsychopharmacology and the Schizophrenia International Research Society and is on the editorial board for numerous leading journals in the field. Tony has made a substantial impact on the field, publishing more than 300 articles (H index 92) spanning basic and clinical research, and has been cited nearly 30,000 times. Tony is one of a handful of individuals that not only performs important basic research, but can to integrate this work into testable models relevant to the human condition.
AWARD WINNERS & FEATURED SPEAKERS

Saturday, January 13, 2018 from 9:00 AM – 11:00 AM
ADHD Treatment and Risk for Substance Abuse Disorders

Tim Wilens, M.D.
Massachusetts General Hospital

Dr. Wilens is Chief of Child and Adolescent Psychiatry, and (Co) Director of the Center for Addiction Medicine at the Massachusetts General Hospital. Dr. Wilens specializes in the diagnosis and treatment of ADHD, substance use disorders, and bipolar disorder. Widely published, Dr. Wilens has more than 350 original articles, reviews, chapters, books and editorials to his credit. Dr. Wilens is a consultant to the National Football League, Major/Minor League Baseball, Bay Cove Human Services and Phoenix House and is consistently named one of the Best Doctors in Boston and in America for psychiatry.
Saturday, January 13, 2018 from 9:00 AM – 11:00 AM

**Health Outcomes of ADHD: Do They Adversely Impact Life Expectancy?**

**Russell Barkley, Ph.D.**
Virginia Commonwealth University Medical Center

Russell A. Barkley, Ph.D., is a Clinical Professor of Psychiatry at the Virginia Treatment Center for Children and Virginia Commonwealth University Medical Center, Richmond, VA. He is a Diplomate (board certified) in three specialties, Clinical Psychology (ABPP), Clinical Child and Adolescent Psychology, and Clinical Neuropsychology (ABCN, ABPP). Dr. Barkley is a clinical scientist, educator, and practitioner who has published 23 books, rating scales, and clinical manuals numbering 41 editions. He has also published more than 270 scientific articles and book chapters related to the nature, assessment, and treatment of ADHD and related disorders. He is the founder and Editor of the bimonthly clinical newsletter, The ADHD Report, now in its 25th year of publication. Dr. Barkley has presented more than 800 invited addresses internationally and appeared on nationally televised programs such as 60 Minutes, the Today Show, Good Morning America, CBS Sunday Morning, CNN, and many other programs on behalf of those with ADHD. He has received awards from the American Psychological Association, American Academy of Pediatrics, American Board of Professional Psychology, Association for the Advancement of Applied and Preventive Psychology, American Professional Society for ADHD and Related Disorders, New England Educational Institute, the Wisconsin Psychological Association, and Children and Adults with ADHD (CHADD) for his career accomplishments, contributions to research in ADHD, to clinical practice, and for the dissemination of science. His websites are www.russellbarkley.org and ADHDLectures.com
Saturday, January 13, 2018 from 9:00 AM – 11:00 AM
The Risks and Benefits of ADHD Medication: A Pharmacoepidemiologic Perspective

Brian D’Onofrio, Ph.D.
Indiana University

Brian D’Onofrio is a Professor and the Director of Clinical Training in the Department of Psychological and Brain Sciences at Indiana University in Bloomington, IN. He received his doctorate from the University of Virginia in 2005 after completing his clinical internship at Children’s Hospital Boston/Harvard Medical School. His research focuses on the causes and treatment of psychological disorders using large-scale datasets and advanced epidemiologic methods. He has worked with several international research teams and has received funding from the NIMH, NICHD, NIDA, NSF, American Foundation for Suicide Prevention, NARSAD, Indiana Clinical and Translational Sciences Institute, Indiana University, and international funding agencies.
AWARD WINNERS & FEATURED SPEAKERS

Sunday, January 14, 2018 from 9:00 AM – 10:30 AM

ADHD: Progress in Identifying Genetic and Environmental Risk Factors

Anita Thapar, FRC.Psych, F.Med.Sci.
Cardiff University

Anita heads the academic Child & Adolescent Psychiatry section at the Division of Psychological Medicine and Clinical Neurosciences, Cardiff University and also directs the developmental disorders group within the MRC Centre for Neuropsychiatric Genetics and Genomics.

Her research focuses on the origins, development and complications of child neurodevelopmental disorders focusing mainly on ADHD. Currently funded research investigations focus on the natural history of ADHD and Autism into adult life, preterm birth and its genetic links with neurodevelopmental disorders and the contribution of genetic and early life exposures to ADHD and ASD trajectories.

Anita trained in Medicine, Psychiatry and Child and Adolescent Psychiatry in Cardiff and South Wales. She was Senior Lecturer in Child and Adolescent Psychiatry at the University of Manchester between 1996 and 1999. She then became the first Professor in Child and Adolescent Psychiatry in Wales in 1999 and developed research, teaching and a specialist clinical service (an NHS tertiary service for child neurodevelopmental disorders and “transition” ADHD clinic for 15 to 25-year olds).

In 2015, she served as lead editor (together with Dr. Daniel S. Pine, NIMH) of the authoritative international textbook Rutter’s Textbook of Child and Adolescent Psychiatry. Anita was awarded a CBE for services to Child and Adolescent Psychiatry in 2017, the President’s Medal from the Royal College of Psychiatrists in 2015 for contributions to policy, public knowledge, education and meeting population and patient care needs and the Ruane Prize 2015 from the Brain and Behavior Research Foundation, USA for outstanding Child & Adolescent Psychiatric research.

She is married to a GP and has two sons.

https://www.cardiff.ac.uk/people/view/126769-thapar-anita
Sunday, January 14, 2018 from 9:00 AM – 10:30 AM

Beyond Heritability – Have Studies of the Effects of Institutional Deprivation Changed How We Conceptualise ADHD?

King’s College London

Edmund Sonuga-Barke is currently Professor of Developmental Psychology, Psychiatry and Neuroscience working in the Department of Child and Adolescent Psychiatry at the Institute of Psychology, Psychiatry and Neuroscience, King’s College London. He also holds Visiting Chairs at Ghent University, Aarhus University and the University of Sussex. He is Editor in Chief of the Journal of Child Psychology and Psychiatry.

His work integrates Developmental Psychopathology and Neuroscience perspectives to employing basic developmental science approaches to study the pathogenesis of neuro-developmental and mental health conditions; their underlying genetic and environmental risks, mediating brain mechanisms and developmental outcomes. He has a particular interest in ADHD and related disorders.

In 2016, Prof Sonuga-Barke was elected a Fellow of the Academy of Medical Sciences.
AWARD WINNERS & FEATURED SPEAKERS

Sunday, January 14, 2018 from 11:00 AM – 12:30 PM
ADHD as a Brain Disorder: Why Is This So Difficult to Establish?

Stephen Faraone, Ph.D.
SUNY Upstate Medical University

Stephen Faraone, Ph.D., is a Distinguished Professor in the Departments of Psychiatry and Neuroscience & Physiology at SUNY Upstate Medical University and Director of Medical Genetics Research for the University. He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital and a lecturer at Harvard Medical School. Prof. Faraone is Chair of the ADHD Subgroup of the Psychiatric Genomics Consortium (PGC) and is a founding member of the PGC Coordinating Committee. He is also Editor of Neuropsychiatric Genetics. An author on over 800 journal articles, editorials, chapters and books, he was the eighth highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI, Science, 2000, Vol 288, pg 959). In 2005, ISI determined him to be the second highest cited author in the area of Attention Deficit Hyperactivity Disorder (http://www.esi-topics.com/add/interviews/StephenFaraone.html) and in 2013 he was the third most highly cited researcher in psychiatry and psychology (http://academic.research.microsoft.com/). His lifetime H-Index as of Feb 2016 was 171.
Barbara Franke is a Professor of Molecular Psychiatry at the Radboud University in Nijmegen, The Netherlands, based at the departments of Human Genetics and Psychiatry of the Radboud University Medical Center. She is also Principal Investigator at the Donders Institute for Brain, Cognition and Behaviour in Nijmegen. At Radboudumc, she is the Chief of the Division of Genome Research and Leader of the Radboud Research Theme Neurodevelopmental Disorders.

As a biologist and geneticist, her research is focused on understanding the biology of (neurodevelopmental) psychiatric disorders, with a particular focus on ADHD. In addition to performing gene-finding studies, she uses bioinformatics, neuroimaging genetics, and small animal models to map biological pathways leading from gene to disease. She is the founder of the International Multicenter persistent ADHD Collaboration (IMpACT) and the coordinator of several international consortia funded by the European Union, including the Aggressotype and MiND projects on ADHD comorbidity with aggression and autism. She also is a founding member and member of the central support group of the ENIGMA consortium on neuroimaging and genetics in health and disease and leads the ADHD Working Group within ENIGMA. Barbara Franke has co-authored over 350 papers, her current H-factor is 70. She has received several prizes and awards, including Aspasia and Vici awards from the Netherlands Organization for Scientific Research (NWO) and the Radboud Hermesdorf International Prize 2013. She is an elected member of the Royal Netherlands Academy of Arts and Sciences, the Royal Holland Society of Sciences and Humanities, and Academia Europaea.
AWARD WINNERS & FEATURED SPEAKERS

Sunday, January 14, 2018 from 11:00 AM – 12:30 PM

ADHD as a Brain Disorder: Why Is This So Difficult to Establish?

John Gabrieli, Ph.D.
Massachusetts Institute of Technology

John Gabrieli is the director of the Athinoula A. Martinos Imaging Center at the McGovern Institute. He is an Investigator at the Institute, with faculty appointments in the Department of Brain and Cognitive Sciences and the Institute for Medical Engineering & Science, where he holds the Grover Hermann Professorship. He also has appointments in the Department of Psychiatry at Massachusetts General Hospital and the Harvard Graduate School of Education, and is the director of the MIT Integrated Learning Initiative. Prior to joining MIT in 2005, he spent 14 years at Stanford University in the Department of Psychology and Neurosciences Program. He received a Ph.D. in Behavioral Neuroscience in the MIT Department of Brain and Cognitive Sciences and a B.A. in English from Yale University. In 2016 he was elected to the American Academy of Arts and Sciences.
AWARD WINNERS & FEATURED SPEAKERS

Sunday, January 14, 2018 from 11:00 AM – 12:30 PM

ADHD as a Brain Disorder: Why Is This So Difficult to Establish?

Jay Giedd, M.D.
University of California San Diego

Jay N. Giedd, M.D. is a professor in the Department of Psychiatry at the University of California, San Diego, and Director of the Division of Child and Adolescent Psychiatry at UCSD and Rady Children’s Hospital-San Diego. In addition, he is an adjunct professor at Johns Hopkins School of Public Health in the Department of Family and Reproductive Medicine and at Fukui University, Japan. Over the past 26 years Dr. Giedd has combined brain imaging, genetics, and behavioral analysis to explore the path, mechanisms, and influences of brain development in health and illness. As one of the most highly cited child psychiatrist of his generation, his over 300 scientific publications have had a transformative impact on medicine, psychology, education, judicial, and public policy. Throughout his career he has maintained a strong personal, clinical, and research interest in ADHD. A member of the CHADD Hall of Fame, he is amongst a group of researchers who uses genetics and neuroimaging to help characterize the neurobiology of ADHD with the goal of seeking to improve interventions and reduce public misconceptions about the illness. His recent work has focused on how new insights from pediatric neuroscience can be used to optimize the environment for healthy brain development, particularly regarding education and the use of digital technologies that have transformed the way youth learn, play, and interact with each other. For his outreach to students of all ages and frequent talks to parents, teachers, mental health workers, legislators, and the general public, Dr. Giedd was honored as co-recipient of the 2012 Society for Neuroscience’s Science Educator Award.
ACKNOWLEDGEMENTS

Program Committee Members

Jeffrey Newcorn, M.D.  
*Program Committee Chair*  
Icahn School of Medicine at Mount Sinai

Scott Kollins, Ph.D.  
*Program Committee Co-Chair*  
Duke University

Lenard Adler, M.D.  
New York University School of Medicine

Kathleen Nadeau, Ph.D.  
Chesapeake ADHD Center of Maryland

Joseph Biederman, M.D.  
Massachusetts General Hospital

Luis Rohde, M.D.  
Federal University of Rio Grande Do Sul

Lisa Chiu, N.P.  
Seattle Children’s Hospital

Steven Pliszka, M.D.  
University of Texas San Antonio

Frances Levin, M.D.  
Columbia University Medical Center

Russell Schachar, M.D.  
University of Toronto

APSARD Officers and Board

Mark Stein, Ph.D, ABPP  
*President*  
Seattle Children’s Hospital

Betsy Busch, M.D., FAAP  
*Secretary*  
Tufts University School of Medicine

Joseph Biederman, M.D.  
*President Elect*  
Massachusetts General Hospital

Vatsal Thakkar, M.D.  
*Treasurer*  
New York University School of Medicine

Anthony Rostain, M.D., MA  
*Past President*  
University of Pennsylvania
ACKNOWLEDGEMENTS

APSARD Officers and Board (continued)

Thomas Brown, Ph.D.
Keck School of Medicine of
University of Southern California

Stephen Faraone, Ph.D.
SUNY Upstate Medical University

Robert Findling, M.D., MBA
Johns Hopkins School of Medicine

Tanya Froehlich, M.D.
Cincinnati Children’s Hospital
Medical Center

Sam Goldstein, Ph.D.
Journal of Attention Disorders

David Goodman, M.D.
Johns Hopkins School of Medicine

John Heiligenstein, M.D.
Pharmaceutical Industry

J.J. Sandra Kooij, M.D., Ph.D.
PsyQ, Psycho-Medical Programs,
The Hague

Keith McBurnett, Ph.D.
University of California, San
Francisco

Iris Manor, M.D.
Tel Aviv University

Greg Mattingly, M.D.
Washington University School of
Medicine

Jeffrey Newcorn, M.D.
Icahn School of Medicine at Mount
Sinai

Andrew Nierenberg, M.D.
Massachusetts General Hospital

Russell Ramsay, Ph.D.
University of Pennsylvania

Mary Solanto, Ph.D.
New York University School of
Medicine

Thomas Spencer, M.D.
Harvard Medical School

Craig Surman, M.D.
Massachusetts General Hospital

Roberta Waite, Ed.D
Drexel University

Margaret Weiss, M.D., Ph.D.
University of British Columbia
Children and Women’s Health Centre
MEETING ANNOUNCEMENTS

Meeting Services

Registration Desk Hours:
Friday, January 12      2:00 PM – 7:00 PM
Saturday, January 13    7:00 AM – 6:00 PM
Sunday, January 14      7:30 AM – 4:00 PM

*The registration/meeting information desk is located in the Thurgood Marshall Foyer on the Mezzanine Level.

The APSARD Speaker Ready Room is open on the below dates and times for presenters to upload slides. The meeting organizers ask that all speakers upload their slides 4 hours prior to their scheduled presentation time.

The Speaker Ready Room is located in the Taft Meeting Room on the Mezzanine Level.
Friday, January 12      1:00 PM – 6:00 PM
Saturday, January 13    7:00 AM – 5:30 PM
Sunday, January 14      7:00 AM – 3:00 PM

Americans with Disabilities Act - It is the policy of APSARD not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3083 or send an email to info@apsard.org.

APSARD Mobile App- The APSARD mobile app is now available in the app store for iPhones and in Google Play for Androids. Search APSARD2018 and download today! View the latest schedule, attendee list and abstracts!
MEETING ANNOUNCEMENTS

Continuing Education Credits

Continuing Education Credits are available for physicians, psychologists and nurses. Applications for credit must be completed online with the meeting evaluation. The evaluation may be completed after the conference at www.APSARD.org/meeting/program. Evaluations for continuing education credit must be submitted no later than February 9, 2018.

Disclosures

Disclosures are available for all APSARD Annual Meeting presenters online at www.APSARD.org/meeting/program. It is the policy of the APSARD to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Accreditation Statements

This meeting is jointly sponsored by the American Professional Society of ADHD and Related Disorders and AMEDCO.

Continuing Education Credit Information:

Satisfactory completion

Participants must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. NOTE: If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
MEETING ANNOUNCEMENTS

Physicians
Accreditation Statement – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and American Professional Society of ADHD & Related. Amedco is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement – Amedco designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by Amedco and American Professional Society of ADHD & Related. Maximum of 14.00 contact hours.

Psychologists
This course is co-sponsored by Amedco and American Professional Society of ADHD & Related. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. 14.00 hours.

Professional Counselors in these 37 states can submit APA = AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KY, KS, ME, MO, NC, ND, NH, NE, NJ, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WI, WY AL / Counselors: Activities not providing NBCC approval may be approved by the Board for individual licensees upon receipt of acceptable documentation prior to the activity. Please send course details to your licensing board for approval BEFORE the event. No approvals afterward by the board.

MFT’s in these 31 states can submit APA = AK, AR, AZ, CA, CO, CT, DE, FL, IA, ID, IN, KS, ME, MO, NE, NC, NH, NM, NJ, NV, OK, OR, PA, SC, SD, TN, TX, UT, VA, WI, WY

Addictions Professionals in these 25 states can submit APA = AK, AR, CO, CT, DE, GA, IA, IN, KS, LA, MO, MT, NE, NM, NC, ND, NJ, NV, NY (outstate held), OK, OR, SC, UT, WA, WI, WY

Social Workers in these 22 states can submit APA = AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY
Social Workers
Amedco, #1346, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. Amedco maintains responsibility for the program. ASWB Approval Period: 6/24/2016 to 6/24/2019. Social workers should contact their regulatory board to determine course approval for continuing education credits.

Social workers participating in this course may receive up to 14.00 clinical continuing education clock hours.

Professional Counselors in these 30 states can submit ASWB = AK, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, ME, MO, ND, NE, NM, NH, NV, OK, PA, TN, TX, UT, VA, WI, WY
AL / Counselors: Activities not providing NBCC approval may be approved by the Board for individual licensees upon receipt of acceptable documentation prior to the activity. Please send course details to your licensing board for approval BEFORE the event. No approvals afterward by the board.

MFT’s in these 25 states can submit ASWB = AK, AR, AZ, CA, CO, FL, IA, ID, IN, KS, ME, MO, NC, NE, NH, NM, NV, OK, PA, TN, TX, UT, VA, WI, WY

Addictions Professionals in these 21 states can submit ASWB = AK, CA, CO, CT, GA, IA, IN, KS, LA, MO, MT, ND, NM, NV, OK, OR, SC, WA, WI, WV, WY

All participants who request continuing education credits by February 9, 2018, should expect to receive their statement of credits via email in March.

The Meeting Evaluation Survey will be available at www.APSARD.org. We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits must complete the survey in order to obtain credits. Your candid input on the 2018 meeting is appreciated as we strive to improve the meeting each year.
APSARD would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

**Pfizer**

**Supernus Pharmaceuticals**

**APSARD Society Support**
APSARD would like to thank the following sponsors for their generous donations to the society:

**Platinum Sponsor:**

![Shire](image)

**Bronze Sponsors:**

![akILI](image)  ![IRONSHORE PHARMACEUTICALS](image)  ![KemPharm, INC](image)

**Exhibitors**
Please visit the exhibitors in the Exhibit Hall C Foyer during the meeting.

- Arbor Pharmaceuticals
- CHADD
- Ironshore Pharmaceuticals
- NLS-1 Pharma Inc.
- Qbtech
- Reimbursify
- Rhodes Pharmaceuticals
- Shire Pharmaceuticals
- Tris Pharmaceuticals
- The TOVA Company
- Vaya Pharmaceuticals

*Please note, due to print deadlines there may be additional exhibitors or supporters not listed in this program.*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 PM – 7:00 PM</td>
<td>Registration Open</td>
<td>Thurgood Marshall Foyer – Mezzanine Level</td>
</tr>
<tr>
<td>5:30 PM – 7:30 PM</td>
<td>Welcome and Opening Plenary Session: <em>ADHD and Cognition</em></td>
<td>Thurgood Marshall Ballroom</td>
</tr>
<tr>
<td>7:30 PM – 9:00 PM</td>
<td>Reception and Poster Viewing</td>
<td>Exhibit Hall C</td>
</tr>
</tbody>
</table>
FRIDAY, JANUARY 12, 2018

1:00 PM – 3:00 PM  
**APSARD Board Meeting (By Invitation)**
Hoover

2:00 PM – 7:00 PM  
**APSARD Registration**
Thurgood Marshall Foyer

3:30 PM – 5:00 PM  
**APSARD Membership Committee (By Invitation)**
Coolidge

3:30 PM – 5:00 PM  
**APSARD Social Media and Education Committee Meeting (By Invitation)**
Harding

5:30 PM – 7:30 PM  
**Welcome and Opening Plenary Session:**  
*ADHD and Cognition*  
Thurgood Marshall Ballroom

**Chair:** Philip Asherson, Kings College London

*ADHD and the Wandering Mind: A New Perspective on Inattention in ADHD*  
Philip Asherson, Kings College London

*The Translational Neuropsychopharmacology of ADHD*  
Trevor Robbins, University of Cambridge

*Tonic-Phasic Dopamine Regulation of Limbic System Integration in the Pathophysiology and Treatment of ADHD*  
Anthony Grace, University of Pittsburgh

**Overall Abstract:** This session will outline different models of cognitive and neural processes that underlie the symptoms, impairments and treatment response to medication in ADHD. The three speakers focus on different models of ADHD. First, Professor Asherson discusses the potential role of mind wandering as a core feature of the ADHD mental state, linked to aberrant regulation of default mode and salience network activity. This model is closely aligned to the default mode interference model and highlights early sensory deficits in addition to difficulties with executive...
control. Second, Professor Robbins discusses the role of noradrenaline and dopamine in sustained attention, working memory and impulse control; highlighting the lack of detailed information on the mechanisms by which changes in catecholamine functioning lead to the changes in cortico-striatal networks seen in ADHD. Finally, Professor Grace discusses in detail the paradoxical effects of stimulants in ADHD and controls. Dopamine system activity is characterized into two categories: the slowly changing, homeostatic low level tonic transmission, and the rapid, high-amplitude phasic transmission. These two types of transmission furthermore interact to modulate dopamine system responsivity and reduce symptoms such as inattention and hyperactivity when used to treat ADHD. Taken together, these talks provide state a state of the art update on contemporary models of ADHD and the treatment response to medication, highlighting the heterogeneity of the disorder, and areas for further research.

Learning Objectives:
• To understand the role of excessive spontaneous mind wandering in ADHD.
• To understand the role of executive control dysfunctions in ADHD.
• To understand the role of phasic and tonic dopamine neurotransmission and their relationship to ADHD and the treatment response to medication.
• To learn about key models of ADHD and the heterogeneity of processes underlying ADHD symptoms and the treatment response to medication.

7:30 PM – 9:00 PM
Reception and Poster Viewing
Exhibit Hall C
***See pages 55 through 67 for a complete listing of posters.
SCHEDULE AT A GLANCE

SATURDAY, JANUARY 13, 2018

7:00 AM – 6:00 PM  Registration Open
Thurgood Marshall Foyer – Mezzanine Level

7:00 AM – 8:00 AM  APSARD Travel Fellow Breakfast (By Invitation)
Coolidge

7:30 AM – 8:30 AM  Morning Break
Atrium Foyer outside of Exhibit Hall C

8:00 AM – 8:45 AM  President’s Summary: State of APSARD
Thurgood Marshall Ballroom

9:00 AM – 11:00 AM  Plenary Session: New Data on Treatment of
ADHD and Impairments in Adulthood
Thurgood Marshall Ballroom

11:00 AM – 11:30 AM  Coffee Break
Atrium Foyer outside of Exhibit Hall C

11:30 AM – 12:30 PM  Lifetime Achievement Plenary Session: Brain
States and Functions in Transitioning ADHD,
Joseph Sergeant, Ph.D.
Thurgood Marshall Ballroom

12:30 PM – 1:30 PM  Data Blitz Session
Lincoln 3-4

12:30 PM – 2:30 PM  Poster Session with Lunch
Exhibit Hall C

2:30 PM – 4:30 PM  Symposia Sessions

<table>
<thead>
<tr>
<th>ADHD and Technology: The Opportunities and Perils</th>
<th>Outside the Pill Bottle: Assessment and Management of Adult ADHD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thurgood Marshall Ballroom</td>
<td>Lincoln 3-4</td>
</tr>
</tbody>
</table>

4:30 PM – 5:00 PM  Coffee Break
Atrium Foyer outside of Exhibit Hall C
SCHEDULE AT A GLANCE

Saturday, January 13, 2018

5:00 PM – 6:15 PM  Ask the Experts Sessions: Pharmacotherapy
                    Coolidge

5:00 PM – 6:15 PM  Ask the Experts Sessions: Psychosocial and Risk Prevention
                    Hoover

6:15 PM – 7:30 PM  Reception and Poster Viewing
                    Exhibit Hall C
FULL SCHEDULE

SATURDAY, JANUARY 13, 2018

7:00 AM – 6:00 PM  **APSARD Registration**
Thurgood Marshall Foyer

7:00 AM – 8:00 AM  **APSARD Travel Fellow Breakfast (By Invitation)**
Coolidge

7:30 AM – 8:30 AM  **Morning Break**
Exhibit Hall C Foyer

8:00 AM – 8:45 AM  **President’s Summary: State of APSARD**
Thurgood Marshall Ballroom
Mark Stein, University of Washington

9:00 AM – 11:00 AM  **Plenary Session: New Data on Treatment of ADHD and Impairments in Adulthood**
Thurgood Marshall Ballroom

**Chair:** Frances Levin, Columbia University Medical Center

*What Effect Does ADHD Medication Treatment Have on the Later Risk for Substance Use Disorders?*
Timothy Wilens, Massachusetts General Hospital

*Health Outcomes of ADHD: Do They Adversely Impact Life Expectancy?*
Russell Barkley, Virginia Commonwealth University Medical Center

*The Risks and Benefits of ADHD Medication: A Pharmacoepidemiologic Perspective*
Brian D’Onofrio, Indiana University

**Overall Abstract:** There is overwhelming evidence that ADHD increases the risk of substance use disorders (SUDs), as well other medical and psychiatric disorders. While early studies found that pharmacologic treatment of ADHD in childhood reduced the risk of adolescent substance use disorder, this was less evident as adolescents matured into adulthood. Dr. Wilens will present recent data, based on large survey, registry and clinical studies that have found that early childhood pharmacologic treatment prescribed for longer duration reduces the risk of substance use disorder in adolescence.
and early adulthood. Similar to SUDs, other harmful behaviors such as accidental injuries, eating pathology and tobacco use is associated with having ADHD. Based on data collected from the Milwaukee longitudinal study, Dr. Barkley will discuss how these adverse outcomes might impact on life expectancy. Finally, Dr. D’Onofrio will discuss how analyses of large-scale health insurance claims datasets in the US and national registry data in Sweden can elucidate how various adverse outcomes, such as serious substance use problems, accidents, other psychiatric comorbidities are associated with periods of dispensed/non-dispensed ADHD medications within individual comparisons. The implications of these data, both in terms of prevention and mitigating harmful outcomes into adulthood will be discussed.

**Learning Objectives:**

- To learn what factors are associated with reduced risk of developing SUDS among those with ADHD.
- To become knowledgeable of the adverse health outcome associated with ADHD and the potential impact on longevity.
- To become familiar with the various large scale datasets, survey data, and clinical longitudinal studies that may elucidate how the risk of SUD, and other health outcomes, may be mitigated by early intervention and ongoing treatment.

11:00 AM – 11:30 AM  **Coffee Break**
Exhibit Hall C Foyer

11:30 AM – 12:30 PM  **Lifetime Achievement Plenary Session: Brain States and Functions in Transitioning ADHD**
Thurgood Marshall Ballroom

**Chair:** Mark Stein, University of Washington

**Brain States and Functions in Transitioning ADHD**
Joseph Sergeant, Vrije Universiteit Amsterdam

**Overall Abstract:** The 2018 Lifetime Achievement Award is presented to Professor Joseph A. Sergeant. This award recognizes Professor Sergeant’s longstanding dedication to the ADHD field and his substantial achievements in building the science of ADHD and its treatment. Professor Sergeant was the developer of the Cognitive Energetic Model of ADHD, and has subsequently gone on to study various aspects linking clinical and
neuropsychological mechanisms with brain function. He is also the founder of the European Network for Hyperkinetic Disorders (EUNETHYDIS), which has been a highly successful model of collaboration for collaborative research, training, and the development and dissemination of clinical guidelines. We are especially honored to have Professor Sergeant with us because of the impact Eunethydis has had on the recent growth and development of APSARD in the US. Professor Sergeant’s talk will examine the very timely issue of ADHD as a brain-based neuropsychiatric disorder.

Learning Objectives:
- To highlight the study of brain behavior relationships in ADHD from childhood to adulthood.
- To provide an overview of how advances in neuroscience have led to increased understanding of ADHD throughout the world.

12:30 PM – 1:30 PM  Data Blitz Session
Lincoln 3-4

Chair: Joseph Biederman, Massachusetts General Hospital

12:30 PM – 12:35 PM  Introduction

12:35 PM – 12:39 PM  Does Exposure to Parental Substance Use Disorders Increase Offspring Risk for a Substance Use Disorder? A Longitudinal Follow-Up Study Into Young Adulthood
Amy Yule, Harvard Medical School/Massachusetts General Hospital

12:40 PM – 12:44 PM  Do Subsyndromal Manifestations of MDD in Children at Genetic Risk for MDD Predict the Development of Major Depression? A Five-Year Longitudinal Controlled Study
Joseph Biederman, Massachusetts General Hospital

12:45 PM – 12:49 PM  Response Time Adjustment in the Stop Signal Task Serve as a Marker of Reinforcement Learning: Development in Typically Developing and ADHD Children and Adolescents
Russell Schachar, University of Toronto
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 12:50 PM – 12:54 PM | Reverse Microdialysis Studies of d-, l-, & d,l-Amphetamine-Evoked Dopamine and Norepinephrine Release in the Rat Nucleus Accumbens and Prefrontal Cortex  
Paul Glaser, Washington University in St. Louis |
| 12:55 PM – 12:59 PM | Dopamine Modulation of Action Control in a Rodent Model of Attention-Deficit/ Hyperactivity Disorder  
Joman Natsheh, Center for Molecular and Behavioral Neuroscience, Rutgers University |
| 1:00 PM – 1:04 PM | Regional Brain Network Organization Distinguishes the Combined and Inattentive Subtypes of Attention Deficit Hyperactivity Disorder  
Jacqueline Saad, The University of Sydney |
| 1:05 PM – 1:09 PM | Lisdexamfetamine Targets Amygdala Mechanisms That Underlie the Emotional Bias of Cognitive Control: Relation to Clinical Improvement in Adults With ADHD  
Kurt Schulz, Icahn School of Medicine at Mount Sinai |
| 1:10 PM – 1:14 PM | Attention Deficit/Hyperactivity Disorder, School Achievement and the Effect of Medication: Evidence From a Swedish Primary School Population  
Andreas Jangmo, Karolinska Institute |
| 1:15 PM – 1:19 PM | The Association Between ADHD Medication and Seizures  
Kelsey Wiggs, Indiana University |
| 12:30 PM – 2:30 PM | Poster Session With Lunch  
Exhibit Hall C  
***See pages 55 through 67 for a complete listing of posters. |
# FULL SCHEDULE

## Concurrent Symposia Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
</table>
| 2:30 PM – 4:30 PM | **ADHD and Technology: The Opportunities and Perils**  
Thurgood Marshall Ballroom | Chair: Russell Schachar, University of Toronto |

### 2:30 PM – 2:40 PM
- **Introduction**

### 2:40 PM – 3:00 PM
- **Technology, Big Data, and Predicting Behavioral Health Measures**  
Brenda Curtis, Perelman School of Medicine  
University of Pennsylvania

### 3:00 PM – 3:20 PM
- **Digital Therapeutics for the Treatment of ADHD: Results From a Large-Scale Randomized Clinical Trial**  
Scott Kollins, Duke University

### 3:20 PM – 3:40 PM
- **The Use of Big Data to Address Clinical Issues**  
Joseph Biederman, Massachusetts General Hospital

### 3:40 PM – 4:00 PM
- **Excessive Newborn Stimulation and Subsequent Attentional Capacity**  
Dimitri Christakis, Seattle Children’s Research Institute

### 4:00 PM – 4:30 PM
- **Discussion**

---

**Overall Abstract:** Every new technology created by mankind seems to afford advantages and disadvantages to society as a whole. Many recent technological developments can negatively impact people’s mental health. The internet can become an obsession to the point of addiction, overstimulation arising from mobile devices and games can adversely impact attention, cognition, and sleep and social media are reshaping the way we relate to one another. Each of these effects are of substantial importance to mental health professionals. Paradoxically, these same devices, computers and media allow access to large scale data that is providing unpresented new insights into the mechanism of mental illness, shaping new technology-
based treatments for ADHD and creating new ways of communicating with our patients to promote positive health behaviors. ADHD scientists and practitioners have eagerly embraced these new technologies as this symposium will reveal. This symposium will address the potential of digital platforms to promote positive mental health in humans and over-stimulation in animals, the effectiveness of specially designed computer games for treating the cognitive manifestations of ADHD, and the utility of electronic medical records (EMR) for evaluation of cardiac adverse effects of antidepressants in youth and for assessment of adherence to stimulant treatment in ADHD.

**Learning Objectives:**
- Be able to describe the results of recent trials of cognitive remediation for ADHD.
- Illustrate how electronic medical records can be used to address important clinical questions in ADHD.
- Be able to describe the effects of excessive non-normative stimulation during infancy.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30 PM – 4:30 PM</td>
<td><strong>Outside the Pill Bottle: Assessment and Management of Adult ADHD</strong></td>
</tr>
<tr>
<td></td>
<td>Lincoln 3-4</td>
</tr>
</tbody>
</table>

**Chair:** Mark Stein, University of Washington

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30 PM – 2:40 PM</td>
<td>Introduction</td>
</tr>
<tr>
<td>2:40 PM – 3:00 PM</td>
<td><strong>Collaboration Between Prescribers and Other Clinicians in Managing ADHD</strong></td>
</tr>
<tr>
<td></td>
<td>Thomas Brown, Keck School of Medicine of University of Southern California</td>
</tr>
<tr>
<td>3:00 PM – 3:20 PM</td>
<td><strong>If a Neuropsychological Evaluation is Not Needed for Diagnosis, What Does It Add to Diagnosis and Treatment of ADHD?</strong></td>
</tr>
<tr>
<td></td>
<td>Jeanette Wasserstein, Mt. Sinai Medical College</td>
</tr>
<tr>
<td>3:20 PM – 3:40 PM</td>
<td><strong>Still Distracted After All These Years: Exploring the World of ADHD After Age 60</strong></td>
</tr>
<tr>
<td></td>
<td>Kathleen Nadeau, Chesapeake ADHD Center of Maryland</td>
</tr>
</tbody>
</table>
3:40 PM – 4:00 PM  |  Intentions Into Actions: CBT for Adult ADHD  
J. Russell Ramsay, University of Pennsylvania, Perelman School of Medicine

4:00 PM – 4:30 PM  |  Discussion

**Overall Abstract:** While multimodal treatment and collaboration between prescribers and mental health providers is common in pediatric ADHD, psychosocial treatment and collaborative and integrative care models are still emerging. The workshop will highlight complexities, barriers, and lessons learned in managing the adult ADHD patient as perspectives on diagnosis, management, and treatment will be provided by several non-prescribing providers.

**Learning Objectives**
- Increase familiarity with the presentation and evaluation of adults with ADHD, including role of testing.
- Describe psychotherapeutic approaches that complement pharmacological interventions in the adult patient.
- Increase awareness of how ADHD presents in older adult compared to other age groups.

4:30 PM – 5:00 PM  |  Coffee Break  
Exhibit Hall C Foyer

5:00 PM – 6:15 PM  |  Ask the Experts: Psychosocial and Risk Prevention  
Hoover

**Participants:**
Kevin Antshel, Syracuse University  
Russell Barkley, Virginia Commonwealth University Medical Center  
Brooke Molina, University of Pittsburgh  
Ronna Fried, Massachusetts General Hospital & Harvard Medical School
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 PM – 6:15 PM</td>
<td>Ask the Experts: Pharmacotherapy</td>
<td>Coolidge</td>
</tr>
<tr>
<td>Participants:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lenard Adler, NYU School of Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jay Giedd, University of California San Diego</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adelaide Robb, Children’s National Health Systems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timothy Wilens, Massachusetts General Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janet Wozniak, Massachusetts General Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:15 PM – 7:30 PM</td>
<td>Reception and Poster Viewing</td>
<td>Exhibit Hall C</td>
</tr>
</tbody>
</table>

SCHEDULE AT A GLANCE

SUNDAY, JANUARY 14, 2018

7:00 AM – 8:00 AM  International Committee Breakfast and Business Meeting (By Invitation)
                   Coolidge

7:30 AM – 4:00 PM  Registration Open
                   Thurgood Marshall Foyer – Mezzanine Level

7:30 AM – 8:30 AM  Morning Break
                   Atrium Foyer outside of Exhibit Hall C

8:15 AM – 9:00 AM  APSARD Business Meeting
                   Thurgood Marshall Ballroom

9:00 AM – 10:30 AM Plenary Session: Environmental and Genetic Influences on ADHD
                   Thurgood Marshall Ballroom

10:30 AM – 11:00 AM Coffee Break
                 Atrium Foyer outside of Exhibit Hall C

11:00 AM – 12:30 PM Plenary Session: ADHD as a Brain Disorder: Why is This So Difficult to Establish?
                   Thurgood Marshall Ballroom

12:30 PM – 2:30 PM  Lunch Session with Poster Viewing
                    Exhibit Hall C

12:30 PM – 2:30 PM  Lunch Discussion Groups

| ADHD in the Prison System | International Perspectives on ADHD |
| Thurgood Marshall Ballroom  | Lincoln 3-4 |

2:30 PM – 4:30 PM  Symposia Sessions

| New Perspectives on ADHD and Mood Dysregulation | Emerging Evidence for the Effectiveness of ADHD Coaching |
| Thurgood Marshall Ballroom  | Lincoln 3-4 |
FULL SCHEDULE

SUNDAY, JANUARY 14, 2018

7:00 AM – 8:00 AM  International Committee Breakfast and Business Meeting (By Invitation)
                     Coolidge

7:30 AM – 4:00 PM  APSARD Registration
                     Thurgood Marshall Foyer

7:30 AM – 8:30 AM  Morning Break
                     Exhibit Hall C Foyer

8:15 AM – 9:00 AM  APSARD Business Meeting
                     Thurgood Marshall Ballroom

9:00 AM – 10:30 AM  Plenary Session: Environment and Genetic Influences on ADHD
                     Thurgood Marshall Ballroom

**Genetics and Environmental Factors**

**Chair:** Jeffrey Newcorn, Mount Sinai Medical Center

**ADHD: Progress in Identifying Genetic and Environmental Risk Factors**
Anita Thapar, Cardiff University

**Beyond Heritability – Have Studies of the Effects of Institutional Deprivation Changed How We Conceptualise ADHD?**
Edmund Sonuga-Barke, King’s College London

**Overall Abstract:** Although ADHD is a highly heritable disorder, simple genetic approaches have not been able to account for the disorder. Recent findings highlight the importance of complex genetic strategies and the aggregate effects of multiple genetic risk factors. There are also a number of well-documented environmental and psychosocial risk factors, which presumably augment, interact with and potentially modify genetic predisposition. This plenary session will explore genetic and environmental risk factors for ADHD, reviewing the latest findings regarding what is known about each. The session will additionally illustrate how recent genetic findings have been incorporated into large-scale epidemiologic studies (Thapar), and the longitudinal course of youth raised in extreme environments who suffered the effects of massive psychosocial deprivation (Sonuga-Barke).
Learning Objectives:
• Attendees will learn about genetic loci that have been implicated in ADHD, and how these can be used in clinical and epidemiological research.
• Attendees will learn about leading environmental causes of ADHD, and the impact of extreme deprivation on the development of ADHD symptoms.

10:30 AM – 11:00 AM  Coffee Break
Exhibit Hall C Foyer

11:00 AM – 12:30 PM  Plenary Discussion Session: ADHD as a Brain Disorder: Why Is This So Difficult to Establish?
Thurgood Marshall Ballroom

Chair: Stephen Faraone, SUNY Upstate Medical University

Participants:
Barbara Franke, Radboud University Medical Center
Stephen Faraone, SUNY Upstate Medical University
John Gabrieli, Massachusetts Institute of Technology
Jay Giedd, University of California San Diego

Overall Abstract: This plenary symposium will first briefly present the results of recent mega-analyses comparing brain volumes between ADHD patients and control participants. This will include previously published data about subcortical structures and new data about cortical structures. The controversy engendered by the subcortical publication will be described and then the plenary panel will present their views of the question “How do we view ADHD as a brain disorder in light of the ENIGMA ADHD results?” Each member of the panel will briefly present their views followed by a panel discussion and participation from the audience.

Learning Objectives:
• Learn about the results from the ENIGMA ADHD analysis of subcortical brain volumes.
• Learn about the results from the ENIGMA ADHD analysis of cortical brain volumes.
• Understand how the ENIGMA ADHD results inform us about the nature of brain abnormalities in ADHD.
• Understand the implications for future research.

12:30 PM – 2:30 PM  Lunch With Poster Viewing
Exhibit Hall C
Concurrent Lunch Discussion Groups

12:30 PM – 2:30 PM  **ADHD in the Prison System**  
Thurgood Marshall Ballroom

**Chair:** Philip Asherson, Kings College London

**Participants:**
Barbara Franke, Radboud University Medical Center  
Jeffrey Stein, Public Defender Service for the District of Columbia (PDS)  
Steven Pliszka, UT Health Science Center at San Antonio

**Overall Abstract:** This symposium will consider the impact of ADHD in relation to adult offending behaviour. Around 20-30% of prisoners are known to meet diagnostic criteria for ADHD. Recent findings from national registry data in Sweden suggests that treatment of ADHD with stimulants or atomoxetine reduces criminal offences by between 30-40%; and reduces violent re-offending on release from prison. To date there has only been one randomised control trial of methylphenidate in prisoners with ADHD, that found a very large effect with a standardised mean difference greater than 2.0. Professor Asherson has completed a pilot study of young adult prisoners and found similar large effects, and is now leading a large-scale randomised control trial to clarify how large are the medication effects compared to placebo. This work suggests that treating ADHD can lead to reductions in criminal behaviour. Independent review from prison inspectors in the UK also noted improvements in behaviour that were highly significant for some prisoners on the ADHD treatment program. Their main concern was the access to treatment and social support would be needed to maintain these benefits on release of patients with ADHD into the community. Although there have been concerns about the potential abuse of ADHD medications in the prison environment, most cases titrated to very low doses, and did not show drug seeking behaviour. Overall the risks of abuse in prison settings appears to be low and no higher than that seen for other ADHD medications.

This symposium will start with a description of these studies of offenders with ADHD from Professor Asherson. The second speaker is Professor Barbara Franke, a leading ADHD investigator based in the Netherlands. Barbara leads the Aggressotype project, a large consortium funded by the European Union to investigate the genetic and neuropathological aetiology of aggression, and the development of novel drug and non-drug treatments such as neurofeedback. The third speaker, Jeff Stein, is a public defender
who says that almost all the people he works with have a history of ADHD plus oppositional defiant disorder. He will give his perspective as someone involved in the legal profession. This symposium will discuss the association of ADHD to criminal behaviour, the delivery of medication treatment in prison settings, and the effects of treatment, and consider the impact of ADHD from a legal perspective. We aim for an interactive discussion with the audience that will highlight the importance of diagnosing and treating ADHD among offenders.

**Learning Objectives:**
- That 20-30% of prisoners meet criteria for ADHD.
- That treatment of ADHD leads to reductions in criminal behavior.
- That treatments for ADHD can be delivered safely in prison settings.
- The impact of ADHD in the legal system.

12:30 PM – 2:30 PM  
**International Perspectives on ADHD**  
Lincoln 3-4

**Chair:** Margaret Weiss, University of Arkansas Medical Sciences

**Participants:**
Iris Manor, Geha MHC  
J.J. Sandra Kooij, PsyQ, Program Adult ADHD, The Hague  
César Soutullo, University of Navarra Clinic DR  
Takuya Saito, Hokkaido University, Graduate School of Medicine  
Edmund Sonuga-Barke, King’s College London

**Overall Abstract:** This symposium takes advantage of the presence of International leaders in the area of ADHD to open discussion about local strengths and challenges in the area of ADHD in different parts of the world. Each speaker will give a brief presentation of key strengths and challenges unique to their location, followed by open discussion of regional differences with audience participation.

**Learning Objectives:**
- Raise awareness of both the similarities and differences of ADHD in North America, Europe, Asia, the Middle East and the British Isles.
- Identify unique local challenges and strengths that can inform a knowledge exchange in which we learn from each other.
- Discuss collaborative initiatives to help grow a global network out of current national networks and facilitate global targets for improved care.
Concurrent Symposia and Workshop Sessions

2:30 PM – 4:30 PM  **New Perspectives on ADHD and Mood Dysregulation**
Thurgood Marshall Ballroom

**Chair:** Andrew Nierenberg, Massachusetts General Hospital

**2:30 PM – 2:40 PM**  Introduction

**2:40 PM – 3:00 PM**  **An Overview of Emotional Dysregulation in ADHD**
Anthony Rostain, University of Pennsylvania, Perelman School of Medicine

**3:00 PM – 3:20 PM**  **Deficient Emotional Self-Regulation in the Context of ADHD**
Joseph Biederman, Massachusetts General Hospital

**3:20 PM – 3:40 PM**  **Affective Circuitry and ADHD**
Jonathan Posner, Columbia University

**3:40 PM – 4:00 PM**  **Emotional Lability in ADHD**
Argyris Stringaris, National Institute of Mental Health

**4:00 PM – 4:30 PM**  Discussion

**Overall Abstract:** While problems with emotional control are not a defining feature of ADHD, they occur in a large number of individuals with ADHD and are frequently associated with a high degree of impairment. Consistent with these clinical findings, studies of underlying neurobiological mechanisms in ADHD point to abnormalities of motivation and emotional regulation, and not just attention and inhibitory control. Yet, it is unknown whether the neural underpinnings of emotional lability in ADHD are unique to ADHD or reflect common features seen across a multiplicity of diagnostic entities. This symposium will examine the nature of emotional dysregulation in youth and adults with ADHD and other disorders, and describe the clinical and neurobiological features which characterize affected individuals.
Learning Objectives:
• Attendees will appreciate the nature of emotional dysregulation in youth with ADHD and learn how the clinical features of emotional dysregulation in youth and adults with ADHD are similar to or different from the characteristics of emotional dysregulation in other disorders.
• Attendees will appreciate the neurobiological mechanisms underlying emotional dysregulation in youth and adults with ADHD and other disorders.

2:30 PM – 4:30 PM  
Emerging Evidence for the Effectiveness of ADHD Coaching  
Lincoln 3-4

Chair: Jodi Sleeper-Triplett, JST Coaching & Training

Participants:
Jodi Sleeper-Triplett, JST Coaching & Training
Elizabeth Ahmann, Maryland University of Integrative Health
Lisa Tuttle, University of Pennsylvania

Overall Abstract: ADHD coaching, which emerged in the 1990s, is a nonclinical behavioral modality that can complement the work of clinicians to improve the performance and well-being of individuals with ADHD across the lifespan.
Coaching is a client-centered wellness model predicated on the view that those coached are creative, resourceful, and whole (Sleeper-Triplett, 2010). In contrast to academic services such as tutoring or learning-strategy instruction, coaching does not prescribe the same set of steps to all participants (e.g., Allsopp, Minskoff, & Bolt, 2005). Instead, coaches are trained to use Socratic questioning and active listening to prompt awareness, reflection, and planning. This process facilitates a client’s ability to clarify personal goals and create realistic plans for achieving them, fostering self-determination.
As with health and wellness coaching, ADHD coaching typically incorporates elements of life coaching, skills coaching, and psychoeducation (Wright, 2014). It draws on current knowledge of the deficits associated with ADHD to inform the coaching relationship co-developed by client and coach (Sleeper-Triplett, 2010). By design, coaching provides a high level of structure and accountability to (a) assist in goal identification, (b) foster behavioral change and goal attainment, (c) promote improvements in functional arenas, and (d) reinforce the maintenance of gains, including
those made in other therapeutic modalities. As such, ADHD coaching is increasingly recognized in the clinical literature as a useful and important component of multimodal treatment (e.g., Barkley, 2015; Kooij et al., 2010; Prevatt & Levrini, 2015; Ramsay, 2010).

This data-driven presentation will provide an overview of ADHD coaching, propose how coaching fits within a multimodal treatment approach, demonstrate the process of ADHD coaching, and provide a descriptive review of extant research (Ahmann et al., 2017; Ahmann et al., in press; Tuttle et al., 2016). A review of the literature to date suggests that ADHD coaching may hold promise in improving functional outcomes and quality of life across the lifespan and contribute positively to multimodal treatment approach.

Learning Objectives:
• Describe three or more aspects of the ADHD coaching process.
• Identify several client outcomes supported by ADHD coaching research.
• Draw conclusions about the potential value of ADHD coaching in multimodal treatment approaches.
## POSTERS

1. **Diagnosis and Treatment Options for Preschoolers With ADHD**
   Sharon Wigal¹, Phillip Chappell², Donna Palumbo*², Shannon Lubaczewski², Sara Ramaker², Richat Abbas²  
   ¹AVIDA Inc., ²Pfizer Inc

2. **Barriers to Evidence-Based ADHD Care for Parents of At-Risk Children**
   Tamara Abu-Ramadan*¹, Lea Taylor¹, Yelim Chung¹, Avery Albert¹, Kevin Antshel¹  
   ¹Syracuse University

3. **Multimodal Psychiatrist-Coach Intervention for ADHD: Case Report Using CARE Guidelines**
   Elizabeth Ahmann*¹, Katherine Smith¹, Laurie Ellington¹, Rebecca O. Pille¹  
   ¹Maryland University of Integrative Health

4. **The Impact of Positive Illusory Bias on Treatment Outcomes Among Adolescents With ADHD**
   Avery Albert*¹, Lea Taylor¹, Tamara Abu-Ramadan¹, Kevin Antshel¹  
   ¹Syracuse University

5. **Multimodal Approach for College Students With ADHD: Combining Exercise and ADHD Coaching**
   Kari Lewis*¹  
   ¹ADHD Behavior Education Services, North Carolina State University

6. **Investigation of Clinical Practice Challenges in the Management of ADHD**
   Greg Mattingly*¹, Rakesh Jain², Jani Hegarty³, Quentin O’Brien³  
   ¹St. Charles Psychiatric Associates, ²Texas Tech Health Sciences, ³Health and Wellness Partners

7. **A Pilot Trial of a Joint Psychosocial Intervention for Behavior and Sleep in Children With a Disruptive Behavior Disorder (DBD)**
   Sara Mills*¹, Brianna Bendixsen², Sue Calhoun¹, Daniel Waschbusch¹, James Waxmonskey¹  
   ¹Pennsylvania State University, College of Medicine, ²Pennsylvania State University, Harrisburg
8. Goal Orientation and Stimulant Misuse in College Students
Lea Taylor*1, Avery Albert1, Tamara Abu-Ramadan1, Kevin Antshel1
1Syracuse University

9. Evidence of Poor Patient Engagement in Treatment for ADHD: A 17-Year Electronic Medical Records Data Mining Study From a Large Health Care Organization
Ronna Fried*1, Joseph Biederman1, Maura Fitzgerald2, Barbara Storch2, Alexa Pulli2, K. Yvonne Woodworth2, Roy Perlis1
1Massachusetts General Hospital & Harvard Medical School, 2Massachusetts General Hospital

10. The Clinical Correlates of Working Memory Deficits in Youth With ADHD: A Comprehensive Literature Review
Ronna Fried*1, Jessica Abrams2, James Chan2, Anna Hall2, Leah Feinberg2, Amanda Pope2, Barbara Storch2, Stephen Faraone3, Joseph Biederman1
1Massachusetts General Hospital & Harvard Medical School, 2Massachusetts General Hospital, 3SUNY Upstate Medical University

11. The Relationship and Predictive Value of Core ADHD Symptoms and Executive Function Deficits
Michael Silverstein1, Stephen Faraone2, Terry L. Leon3, Thomas Spencer4, Joseph Biederman4, Lenard Adler*3
1Drexel University, 2SUNY Upstate Medical University, 3NYU School of Medicine, 4Massachusetts General Hospital

12. Do Subsyndromal Manifestations of MDD in Children at Genetic Risk for MDD Predict the Development of Major Depression? A Five-Year Longitudinal Controlled Study
Joseph Biederman*1, Mai Uchida, MD2, Maura Fitzgerald1, Caroline Kelberman1, Hilary Woodworth1, Nicholas Carrellas1
1Massachusetts General Hospital, 2Massachusetts General Hospital & Harvard Medical School
13. **Sport Concussion and Attention Deficit Hyperactivity Disorder in Student Athletes: A Cohort Study**

Joseph Biederman*, Mary Alexis Iaccarino, Maura Fitzgerald, Alexa Pulli, K. Yvonne Woodworth, Thomas J. Spencer, Ross Zafonte

1Massachusetts General Hospital, 2Spaulding Rehabilitation Hospital & MassGeneral Hospital for Children, 3Massachusetts General Hospital & Harvard Medical School, 4Spaulding Rehabilitation Hospital

14. **Predictive Utility of Autistic Traits in Youth With ADHD: A Controlled 10-Year Longitudinal Follow-Up Study**

Gagan Joshi, Maura Fitzgerald, Stephen Faraone, Janet Wozniak, Ronna Fried, Maribel Galdo, Abigail Belser, Barbora Hoskova, Melissa De Leon, Joseph Biederman*

1Harvard Medical School, Massachusetts General Hospital, 2Massachusetts General Hospital, 3SUNY Upstate Medical University

15. **Parental Stigma About Medical and Mental Health Issues: An Investigation Into the Differential Effects of Parent Gender and Stigma on ADHD Vs. Asthma**

Yelim Chung*, Tamara Abu-Ramadan, Lea Taylor, Kevin Antshel

1Syracuse University

16. **The Impact of ADHD in the Canadian Workplace**

Kathryn Fotinos, Alexa Fine, Tia Sternat, Irvin Epstein, Martin Katzman*

1START Clinic for Mood and Anxiety Disorders

17. **Reward-Based Learning and the Severity of Substance Abuse Risk in Drug-Naive Youth**

Iliyan Ivanov*, Muhammad Parvaz, Kristen Kim, Jeffrey Newcorn

1Mt. Sinai NYC, 2Icahn School of Medicine at Mount Sinai, 3Rutgers University

18. **Sluggish Cognitive Tempo Predicts Academic Fluency in Clinically-Referred Youth, Beyond Contributions of Core Skills, Inattention, and Graphomotor Speed**

Lisa Jacobson*, Mark Mahone

1Johns Hopkins School of Medicine, Kennedy Krieger Institute, 2Kennedy Krieger Institute
19. The Social Context of Alcohol Use Among Young Adults With ADHD Histories
Traci Kennedy*1, Christine Walther2, Sarah Pedersen1, Kirsten McKone1, Elizabeth Gnagy3, William Pelham3, Brooke Molina1
1University of Pittsburgh, 2University of Houston, Clear Lake, 3Florida International University

20. Young Adult Outcomes as a Function of Adolescent ADHD Symptom Trajectories: Inattention, Hyperactivity/Impulsivity, and Oppositional Behavior
Traci Kennedy*1, Christine Walther2, Sarah Pedersen1, Kirsten McKone1, Elizabeth Gnagy3, William Pelham3, Brooke Molina1
1University of Pittsburgh, 2University of Houston, Clear Lake, 3Florida International University

21. Is SCT a Risk Factor for Internalizing Psychopathology?
Keith McBurnett*1, Shaikh Ahmahdh1, Lauren Friedman1, Miguel Villodas2, Linda Pfiffner1
1University of California, San Francisco, 2San Diego State University

22. Prevalence and Impact of Under- or Misdiagnosed ADHD in Adults Referred for the Treatment of Mood and Anxiety Disorders
Tia Sternat*1, Kathryn Fotinos1, Alexa Fine1, Cathy Cameron1, Irvin Epstein1, Martin Katzman1
1START Clinic for Mood and Anxiety Disorders

23. Attention Deficit Hyperactivity Disorder: A Predictive Factor of Treatment-Resistance in Adults Diagnosed With Generalization Anxiety Disorder
Tia Sternat*1, Alexa Fine1, Kathryn Fotinos1, Irvin Epstein1, Martin Katzman1
1START Clinic for Mood and Anxiety Disorders

Natalie Miller*1, Andrea Chronis-Tuscano1, Kathryn Degnan2, Nathan Fox1
1University of Maryland - College Park, 2Catholic University of America
25. Emotion Dysregulation Increases in Cigarette Smokers With ADHD After Smoking Abstinence

John Mitchell*¹, Carl Lejuez², F. Joseph McClernon¹, Jean Beckham³, Scott Kollins¹
¹Duke University Medical Center, ²University of Kansas, ³Durham, NC Veterans Affairs Medical Center

26. OPEN BOARD

27. Descriptive Study of Friendships and Social Networks of Adolescents With ADHD

Barbara Wise*¹
¹Indiana Wesleyan University

28. Further Evidence of High Level of Persistence of Pediatric Bipolar-I Disorder From Childhood Onto Late Adolescent YEARS: A One Year Replication Longitudinal Follow-Up Study

Janet Wozniak*¹, Rebecca Wolenski¹, Maura Fitzgerald¹, Stephen Faraone², Gagan Joshi³, Mai Uchida³, Joseph Biederman³
¹Massachusetts General Hospital, ²SUNY Upstate Medical University, ³Massachusetts General Hospital & Harvard Medical School

29. OPEN BOARD

30. Does Exposure to Parental Substance Use Disorders Increase Offspring Risk for a Substance Use Disorder? A Longitudinal Follow-Up Study Into Young Adulthood

Amy Yule*¹, Timothy Wilens¹, MaryKate Martelon², Joseph Biederman¹
¹Harvard Medical School & Massachusetts General Hospital, ²Massachusetts General Hospital

31. Further Evidence of the Diagnostic Utility of the Child Behavior Checklist for Identifying Pediatric Bipolar I Disorder

Amy Yule*¹, Maura Fitzgerald², Timothy Wilens¹, Janet Wozniak¹, K. Yvonne Woodworth², Alexa Pulli², Mai Uchida¹, Stephen Faraone³, Joseph Biederman¹
¹Harvard Medical School & Massachusetts General Hospital, ²Massachusetts General Hospital, ³SUNY Upstate Medical University & University of Bergen, Norway
32. Screening for ADHD and Impairment in a General Outpatient Psychiatric Sample of Adults
Dara Babinski*1, James Waxmonsky2, Edward Bixler2, Duanping Liao2, Amanda Pearl2, Dahlia Mukherjee2, Daniel Waschbusch2, Erika Saunders2
1Penn State College of Medicine, 2Pennsylvania State University, College of Medicine

33. Item Response Theory Analysis of the Before School Functioning Questionnaire and Parent Rating of Evening and Morning Behavior Scale, Revised in Children With Attention-Deficit/Hyperactivity Disorder
Stephen Faraone*1, Norberto DeSouza2, F. Randy Sallee2, Bev Incledon2, Timothy Wilens3
1SUNY Upstate Medical University, 2Ironshore Pharmaceuticals & Development, Inc., 3Harvard Medical School/Massachusetts General Hospital

34. Social Anxiety and Self-Efficacy in Young Adults With ADHD Symptoms: Assessing the Use of the Adult ADHD Self-Report Scale (ASRS-V1.1) Part A
Tom Buchanan1, Meghan Leahy*2, Roberta Waite3
1Mount Royal University, 2Leahy Learning, 3Drexel University

35. Sluggish Cognitive Tempo in Adult Outpatients Seeking an ADHD Evaluation: A Psychometric Analysis of the BAARS-IV SCT Subscale
Jessica Lunsford-Avery*1, Scott Kollins1, Julia Schechter1, Maggie Sweitzer1, Cara Lusby1, Jessica Solis Sloan1, John Mitchell1
1Duke University Medical Center

36. Latent Class Analysis of Previsit Parent Ratings as Predictors of ADHD Comorbidities
Alison Pritchard*1, Luke Kalb1, T. Andrew Zabel1, Lisa Jacobson1
1Kennedy Krieger Institute

37. Caregiver Survey of the Burden of Disease in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Brigitte Robertson*1, Alexandra Khachatryan1, Michael Andreini2, Steven Blahut2, Eitan Shimko2, Robert Stolper2, Peter S. Jensen3
1Shire, 2Quintiles IMS, 3University of Arkansas for Medical Sciences
38. **At-Home Functional Impairment in Youth With ADHD: Factor Structure and Norm-Referenced Cut-Off Points for the Before School Functioning Questionnaire and Parent Rating of Evening and Morning Behavior Scale, Revised**

Stephen V. Faraone¹, Norberto DeSousa², Rick Nullmeier², Randy Sallee², Beverly Incledon², Timothy Wilens³

¹SUNY Upstate Medical University, ²Ironshore Pharmaceuticals & Development, Inc., ³Harvard Medical School/Massachusetts General Hospital

39. **ADHD Symptoms and Performance on the Children’s Gambling Task**

Sierra Tolbert¹, Caroline Barry¹, Victoria Saba¹, Alesha Majors¹, Bernard Fuemmeler², Scott Kolls¹, Julia Schechter¹

¹Duke University Medical Center, ²Virginia Commonwealth University

40. **Response Time Adjustment in the Stop Signal Task Serve as a Marker of Reinforcement Learning: Development in Typically Developing and ADHD Children and Adolescents**

Russell Schachar¹, Annie Dupuis², Jennifer Crosbie¹, Paul Arnold³, Mohsen Soltanifar¹

¹University of Toronto, ²The Hospital for Sick Children, ³University of Calgary

41. **Copy Number Variants in Brain-Related Genes Are Associated With Neuropsychiatric Traits in Childhood**

Russell Schachar¹, Christie Burton¹, Mehdi Zarrei¹, W. Engchuan¹, Daniel Merico¹, J. MacDonald¹, B. Xiao¹, Andrew Paterson¹, Lisa Strug¹, Christian Marshall¹, Jennifer Crosbie¹, Paul Arnold², Steven Scherer¹

¹University of Toronto, ²University of Calgary

42. **Heritability of Neuropsychological Subtypes in ADHD**

Anne Arnett¹, Bruce Pennington², Erik Willcutt³

¹University of Washington, ²University of Denver, ³University of Colorado

43. **Reverse Microdialysis Studies of d-, l-, & d,l-Amphetamine-Evoked Dopamine and Norepinephrine Release in the Rat Nucleus Accumbens and Prefrontal Cortex**

Paul Glaser¹, Peter Huettl², Francois Pomerleau², Luke Bradley², Meagan Littrell², Greg Gerhardt²

¹Washington Univ. in St. Louis, ²University of Kentucky
44. Dopamine Modulation of Action Control in a Rodent Model of Attention-Deficit/Hyperactivity Disorder

Joman Natsheh*, Michael Shiflett, Marwa Abdelaziz, Emaan Chaudhry, Samanthika Devalaraju, Delia Duran, Victor Lopez, Sydney Pacelli
1Center for Molecular and Behavioral Neuroscience, Rutgers University, 2Rutgers University

45. The Endocytic Regulation of Autophagy and Cell Survival: Pathway Interactions for ADHD- and Autism-Risk Gene SLC9A9

Jameson Patak*, Jonathon Hess, Yanli Zhang-James, Stephen Glatt, Stephen Faroone
1SUNY Upstate Medical University

46. Regional Brain Network Organization Distinguishes the Combined and Inattentive Subtypes of Attention Deficit Hyperactivity Disorder

Jacqueline Saad*, Kristi Griffiths, Michael Kohn, Simon Clarke, Leanne Williams, Mayuresh Korgaonkar
1The University of Sydney, 2Brain Dynamics Centre, The Westmead Institute for Medical Research, The University of Sydney, 3Centre for Research into Adolescents’ Health, Westmead Hospital, 4Stanford University

47. Lisdexamfetamine Targets Amygdala Mechanisms That Underlie the Emotional Bias of Cognitive Control: Relation to Clinical Improvement in Adults With ADHD

Kurt Schulz*, Beth Krone, Lenard Adler, Anne-Claude Bedard, Juan Pedraza, Jeffrey Newcorn
1Icahn School of Medicine at Mount Sinai, 2NYU School of Medicine, 3University of Toronto, 4Mount Sinai Medical Center

48. Searching for Neural Biomarkers of the Risk for Pediatric Mood Disorders: A Controlled fMRI Study in Children

Joseph Biederman*, Mai Uchida, Yuwen Hung, Caroline Kelberman, Schuyler Gaillard, John D. E. Gabrieli
1Massachusetts General Hospital, 2Massachusetts General Hospital & Harvard Medical School, 3Massachusetts Institute of Technology
49. A Prospective Open-Label Trial of Extended-Release Liquid Methylphenidate for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Adults With High-Functioning Autism Spectrum Disorder: An Interim Analysis

Gagan Joshi¹, Barbora Hoskova², Maura Fitzgerald², Tolga Atilla Ceranoglu¹, Amy Yule¹, Craig Surman², Ronna Fried¹, Maribel Galdo¹, Abigail Belser², Melissa De Leon², Joseph Biederman*¹
¹Harvard Medical School & Massachusetts General Hospital, ²Massachusetts General Hospital

50. Therapeutic Response and Side-Effects to Methylphenidate in ADHD: Role of Gender of the Child and the Observer

Venkat Bhat*¹, Natalie Grizenko², Ridha Joober²
¹University of Toronto, ²McGill University

51. Therapeutic Response and Side-Effects in Children With ADHD: Role of Observation Setting

Venkat Bhat*¹, Natalie Grizenko², Ridha Joober²
¹University of Toronto, ²McGill University

52. Therapeutic Response and Side-Effects to Methylphenidate in ADHD: Role of Co-Morbidity

Venkat Bhat*¹, Natalie Grizenko², Ridha Joober²
¹University of Toronto, ²McGill University

53. Single- and Multiple-Dose Pharmacokinetics of KP415, a Novel d-Methylphenidate Product Containing a Prodrug of d-Methylphenidate, in Healthy Volunteers

Rene Braeckman¹, Sven Guenther¹, Travis Mickle¹, Andrew Barrett*¹, Adam Smith¹, Kathryn Roupe², Michael Nutt², Cynthia Zamora²
¹KemPharm, Inc., ²Worldwide Clinical Trials

54. Relationships Between Executive Function Improvement and ADHD Symptom Improvement With Lisdexamfetamine Dimesylate in Adults With ADHD and Executive Function Deficits: A Post Hoc Analysis

Thomas Brown*¹, Yi Chen², Victor Otcheretko², Brigitte Robertson²
¹Keck School of Medicine of University of Southern California, ²Shire
55. Efficacy and Safety of SPN-810 (Extended-Release Molindone) to Treat Impulsive Aggression in Children Being Optimally Treated for Attention-Deficit/Hyperactivity Disorder: Phase 2b and Open-Label Extension Results
Gianpiera Ceresoli-Borroni*, Toyin Adewole¹, Tesfaye Liranso¹, Robert Findling²
¹Supernus Pharmaceuticals, Inc., ²Kennedy Krieger Institute/Johns Hopkins University

56. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of SHP465 Mixed Amphetamine Salts Extended-Release in Children and Adolescents With ADHD: Exploratory Analyses by Age Group
Ann Childress*, Ming Yu², Brian Yan², Brigitte Robertson²
¹Center for Psychiatry and Behavioral Medicine, Inc., ²Shire

57. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children With ADHD
Ann Childress*, Sally A. Berry², Antonio Pardo², Heidi W. Belden²
¹Center for Psychiatry and Behavioral Medicine, Inc., ²Tris Pharma, Inc.

58. Efficacy, Safety, and Tolerability of an Extended-Release, Orally Disintegrating Methylphenidate Tablet in Children 6–12 Years of Age With ADHD: Open-Label, Dose-Optimization Period Outcomes
Ann Childress*, Scott H. Kollins², Andrew J. Cutler³, Andrea Marraffino⁴, Carolyn R. Sykes⁵
¹Center for Psychiatry and Behavioral Medicine, Inc., ²Duke University, ³Meridien Research, ⁴Florida Clinical Research Center, LLC, ⁵Neos Therapeutics, Inc.

59. Approached to Share or Sell Your Meds? College Students With ADHD and Substance-Tolerant Social Environments
Montaya Dawkins*, Heather Joseph², Heidi Kipp³, Engster Stacey⁴, Rachel Lindstrom³, Seth Harty⁵, Bridget Newman⁶, Srihari Bangalor⁷, Brooke Molina⁸
¹University of Pittsburgh Medical Center, Western Psychiatric Institute & Clinic, ²University of Pittsburgh School of Medicine, ³University of Pittsburgh Medical Center, Western Psychiatric Institute & Clinic, ⁴University of Pittsburgh Medical Center, ⁵University of Canterbury, ⁶RTI International, ⁷Roseville Medical Center, ⁸University of Pittsburgh
60. Executive Functioning in Everyday Life in Emerging Adults With ADHD

Ronna Fried*¹, Robert Roth², Peter Isquith³, Maura Fitzgerald⁴, Heidi Boland⁴, Joseph Biederman¹
¹Massachusetts General Hospital & Harvard Medical School, ²Geisel School of Medicine at Dartmouth, ³Harvard Medical School & Geisel School of Medicine at Dartmouth, ⁴Massachusetts General Hospital

61. Modeling the Trajectory of ADHD Symptoms Throughout the Day in Children Treated With Placebo in a Laboratory Classroom Setting Study

Roberto Gomeni*¹, Seth Hopkins², Antony Loebel², Kenneth Koblan²
¹PharmacoMetrica, ²Sunovion Pharmaceuticals Inc.

62. Modeling Exposure-Response of Dasotraline on ADHD Symptoms Throughout the Day in Children With ADHD in a Laboratory Classroom Setting Study

Seth Hopkins*¹, Roberto Gomeni², Antony Loebel¹, Kenneth Koblan¹
¹Sunovion Pharmaceuticals Inc., ²PharmacoMetrica

63. Comparative Bioavailability of DR/ER-MPH, a Delayed-Release and Extended-Release Methylphenidate Formulation, and an Immediate-Release Methylphenidate in Healthy Adult Volunteers

Bev Incledon*¹, Norberto DeSousa¹, F. Randy Sallee¹
¹Ironshore Pharmaceuticals & Development Inc.

64. Attention Deficit/Hyperactivity Disorder, School Achievement and the Effect of Medication: Evidence From a Swedish Primary School Population

Andreas Jangmo*¹, Amanda Stålhandske¹, Ralf Kuja-Halkola¹, Henrik Larsson²
¹Karolinska Institute, ²Karolinska Institute & Örebro University

65. Double-Blind Sham-Controlled Pilot Study of Trigeminal Nerve Stimulation (TNS) for Attention-Deficit/Hyperactivity Disorder (ADHD)

James McGough*¹, Sandra Loo¹, Jennifer Cowen¹, Alexandra Sturm¹, Ian Cook¹
¹David Geffen School of Medicine at UCLA

Jonathan Rubin*¹, David Siner², David Baker²
1Consultant, 2Alcobra Pharma

67. **Understanding Abuse Risk Related to Immediate-Release Amphetamine**

Jonathan Rubin*¹, David Baker², David Siner², Natasha Oyedele³
1Consultant, 2Alcobra Pharma, 3Inflexxion

68. **A Randomized, Open-Label Bioequivalence Study of a New Extended-Release Amphetamine Oral Suspension in Adults**

Carolyn Sikes*¹, Jeffrey Stark², Russ McMahen¹, Dorothy Engelking¹
1Neos Therapeutics, 2Worldwide Clinical Trials,

69. **Pharmacoscintigraphic and Pharmacokinetic Analysis of CTx-1301, a Novel Tri-Modal Oral Formulation for Release of Dexmethylphenidate in Healthy Adults**

Raul Silva*¹, Matt Brams¹, Arthur Straughn¹, Shane Schaffer¹, Steven Abele¹, Howard Stevens², Neil Masson³
1Cingulate Therapeutics, 2BDD Pharma, 3Royal College of Psychiatrists

70. **L-Methylfolate Supplementation to Oros-Methylphenidate Pharmacotherapy in ADHD: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial**

Craig Surman*¹, Tolga Atilla Ceranoglu¹, Carrie Vaudreuil¹, Brittany Albright¹, Mai Uchida¹, Amy Yule¹, Andrea Spencer¹, Heidi Boland¹, Rebecca Grossman¹, Lauren Rhodewalt¹, Maura Fitzgerald¹, Joseph Biederman¹
1Massachusetts General Hospital

71. **Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With ADHD**

Nathan Teuscher*¹, Carolyn Sikes², Russ McMahen², Dorothy Engelking²
1Certara, 2Neos Therapeutics
72. Efficacy and Safety of Dasotraline in Children With Attention Deficit Hyperactivity Disorder: A Laboratory Classroom Study
Sharon Wigal\(^1\), Seth Hopkins\(^2\), Kenneth Koblan\(^2\), Ann Childress\(^3\), Joyce Tsai\(^2\), Jay Hsu\(^2\), Antony Loebel\(^2\), Robert Goldman\(^*2\)
\(^1\)AVIDA Inc., \(^2\)Sunovion Pharmaceuticals Inc., \(^3\)Center for Psychiatry and Behavioral Medicine, Inc.,

73. Dasotraline for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: Pooled Analysis of Two Double-Blind Studies
Lenard Adler\(^1\), Scott Kollins\(^2\), Seth Hopkins\(^3\), Robert Goldman\(^3\), Joyce Tsai\(^3\), Jay Hsu\(^3\), Andrei Pikalov\(^*3\), Kenneth Koblan\(^3\), Antony Loebel\(^3\)
\(^1\)New York University Langone Medical Center, \(^2\)Duke University Medical Center, \(^3\)Sunovion Pharmaceuticals Inc.

74. Efficacy, Safety, Tolerability and PK of Mazindol Controlled Release (CR) in Adults With ADHD
Tim Wigal\(^*1\), Jeffrey Newcorn\(^2\), Sharon Wigal\(^1\), Nelson Handal\(^3\), Iouletta Mulligan\(^4\), Virginia Schmith\(^5\), Eric Konofal\(^6\)
\(^1\)Avida, \(^2\)Mount Sinai Medical Center, \(^3\)Dothan Behavioral Medicine Clinic, \(^4\)Worldwide Clinical Trials, \(^5\)Nuventra Pharma Sciences, \(^6\)Pediatric Sleep Disorders Center

75. The Association Between ADHD Medication and Seizures
Kelsey Wiggs\(^*1\), Zheng Chang\(^2\), Patrick Quinn\(^1\), Kwan Hur\(^3\), Robert Gibbons\(^3\), David Dunn\(^4\), Isabell Brikell\(^2\), Henrik Larsson\(^5\), Brian D’Onofrio\(^1\)
\(^1\)Indiana University, \(^2\)Karolinska Institute, \(^3\)University of Chicago, \(^4\)Indiana University School of Medicine, \(^5\)Karolinska Institute & Örebro University

76. Clinically Meaningful Improvements With DR/ER-MPH in At-Home Functional Impairment During the Early Morning, Late Afternoon, and Evening in Children With Attention-Deficit/Hyperactivity Disorder
Timothy Wilens\(^*1\), Stephen V. Faraone\(^2\), Paul Hammerness\(^3\), Steven Pliszka\(^4\), Norberto DeSousa\(^5\), F. Randy Sallee\(^5\), Bev Incledon\(^5\), Jeffrey Newcorn\(^6\)
\(^1\)Massachusetts General Hospital, \(^2\)SUNY Upstate Medical University, \(^3\)Harvard Medical School, \(^4\)UT Health Science Center at San Antonio, \(^5\)Ironshore Pharmaceuticals & Development, Inc., \(^6\)Mount Sinai Medical Center
## AUTHOR INDEX

<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbas, Richat</td>
<td>55</td>
</tr>
<tr>
<td>Abdelaziz, Marwa</td>
<td>62</td>
</tr>
<tr>
<td>Abele, Steven</td>
<td>66</td>
</tr>
<tr>
<td>Abrams, Jessica</td>
<td>56</td>
</tr>
<tr>
<td>Abu-Ramadan, Tamara</td>
<td>55, 56, 57</td>
</tr>
<tr>
<td>Adewole, Toyin</td>
<td>64</td>
</tr>
<tr>
<td>Adler, Lenard</td>
<td>23, 44, 56, 62, 67</td>
</tr>
<tr>
<td>Ahmahdh, Shaikh</td>
<td>58</td>
</tr>
<tr>
<td>Ahmann, Elizabeth</td>
<td>52, 55</td>
</tr>
<tr>
<td>Albert, Avery</td>
<td>55, 56</td>
</tr>
<tr>
<td>Albright, Brittany</td>
<td>66</td>
</tr>
<tr>
<td>Andreini, Michael</td>
<td>60</td>
</tr>
<tr>
<td>Antshel, Kevin</td>
<td>43, 55, 56, 57</td>
</tr>
<tr>
<td>Arnett, Anne</td>
<td>61</td>
</tr>
<tr>
<td>Arnold, Paul</td>
<td>61</td>
</tr>
<tr>
<td>Asherson, Philip</td>
<td>10, 33, 49</td>
</tr>
<tr>
<td>Babinski, Dara</td>
<td>60</td>
</tr>
<tr>
<td>Baker, David</td>
<td>66</td>
</tr>
<tr>
<td>Bangalor, Srhari</td>
<td>64</td>
</tr>
<tr>
<td>Barkley, Russell</td>
<td>14, 37, 43</td>
</tr>
<tr>
<td>Barrett, Andrew</td>
<td>63</td>
</tr>
<tr>
<td>Barry, Caroline</td>
<td>61</td>
</tr>
<tr>
<td>Beckham, Jean</td>
<td>59</td>
</tr>
<tr>
<td>Bedard, Anne-Claude</td>
<td>62</td>
</tr>
<tr>
<td>Belden, Heidi W.</td>
<td>64</td>
</tr>
<tr>
<td>Belser, Abigail</td>
<td>57, 63</td>
</tr>
<tr>
<td>Bendixsen, Brianna</td>
<td>55</td>
</tr>
<tr>
<td>Berry, Sally A.</td>
<td>64</td>
</tr>
<tr>
<td>Bhat, Venkat</td>
<td>9, 63</td>
</tr>
<tr>
<td>Biederman, Joseph</td>
<td>8, 23, 39, 41, 51, 56, 57, 59, 62, 63, 65, 66</td>
</tr>
<tr>
<td>Bixler, Edward</td>
<td>60</td>
</tr>
<tr>
<td>Blahut, Steven</td>
<td>60</td>
</tr>
<tr>
<td>Boland, Heidi</td>
<td>65, 66</td>
</tr>
<tr>
<td>Bradley, Luke</td>
<td>61</td>
</tr>
<tr>
<td>Braeckman, Rene</td>
<td>63</td>
</tr>
<tr>
<td>Brams, Matt</td>
<td>66</td>
</tr>
<tr>
<td>Brikell, Isabell</td>
<td>67</td>
</tr>
<tr>
<td>Brown, Thomas</td>
<td>24, 42, 63</td>
</tr>
<tr>
<td>Buchanan, Tom</td>
<td>60</td>
</tr>
<tr>
<td>Burton, Christie</td>
<td>61</td>
</tr>
<tr>
<td>Busch, Betsy</td>
<td>23</td>
</tr>
<tr>
<td>Calhoun, Sue</td>
<td>55</td>
</tr>
<tr>
<td>Cameron, Cathy</td>
<td>58</td>
</tr>
<tr>
<td>Carrellas, Nicholas</td>
<td>56</td>
</tr>
<tr>
<td>Ceranoglu, Tolga Atilla</td>
<td>63, 66</td>
</tr>
<tr>
<td>Ceresoli-Borroni, Gianpiera</td>
<td>64</td>
</tr>
<tr>
<td>Chan, James</td>
<td>56</td>
</tr>
<tr>
<td>Chang, Zheng</td>
<td>67</td>
</tr>
<tr>
<td>Chappell, Phillip</td>
<td>55</td>
</tr>
<tr>
<td>Chaudhry, Emaan</td>
<td>62</td>
</tr>
<tr>
<td>Chen, Yi</td>
<td>63</td>
</tr>
<tr>
<td>Childress, Ann</td>
<td>64, 67</td>
</tr>
<tr>
<td>Chiu, Lisa</td>
<td>23</td>
</tr>
<tr>
<td>Christakis, Dimitri</td>
<td>41</td>
</tr>
<tr>
<td>Chronis-Tuscano, Andrea</td>
<td>58</td>
</tr>
<tr>
<td>Chung, Yelim</td>
<td>55, 57</td>
</tr>
<tr>
<td>Clarke, Simon</td>
<td>62</td>
</tr>
<tr>
<td>Cook, Ian</td>
<td>65</td>
</tr>
<tr>
<td>Cowen, Jennifer</td>
<td>65</td>
</tr>
<tr>
<td>Crosbie, Jennifer</td>
<td>61</td>
</tr>
<tr>
<td>Curtis, Brenda</td>
<td>41</td>
</tr>
<tr>
<td>Cutler, Andrew J.</td>
<td>64</td>
</tr>
<tr>
<td>Dawkins, Montaya</td>
<td>64</td>
</tr>
<tr>
<td>Degnan, Kathry</td>
<td>58</td>
</tr>
<tr>
<td>De Leon, Melissa</td>
<td>57, 63</td>
</tr>
<tr>
<td>DeSousa, Noberto</td>
<td>60, 61, 65, 67</td>
</tr>
<tr>
<td>Devalaraju, Samanthika</td>
<td>62</td>
</tr>
<tr>
<td>D’Onofrio, Brian</td>
<td>15, 37, 67</td>
</tr>
<tr>
<td>Dunn, David</td>
<td>67</td>
</tr>
<tr>
<td>Dupuis, Annie</td>
<td>61</td>
</tr>
<tr>
<td>Duran, Delia</td>
<td>62</td>
</tr>
<tr>
<td>Ellington, Laurie</td>
<td>55</td>
</tr>
<tr>
<td>Engchuan, W.</td>
<td>61</td>
</tr>
<tr>
<td>Engelking, Dorothy</td>
<td>66</td>
</tr>
<tr>
<td>Epstein, Irvin</td>
<td>57, 58</td>
</tr>
<tr>
<td>Faraone, Stephen</td>
<td>8, 18, 24, 48, 56, 57, 59, 60, 61, 62, 67</td>
</tr>
<tr>
<td>Feinberg, Leah</td>
<td>56</td>
</tr>
<tr>
<td>Findling, Robert</td>
<td>24, 64</td>
</tr>
<tr>
<td>Fine, Alexa</td>
<td>57, 58</td>
</tr>
<tr>
<td>Fitzgerald, Maura</td>
<td>56, 57, 59, 63, 65, 66</td>
</tr>
<tr>
<td>Fotinos, Kathryn</td>
<td>57, 58</td>
</tr>
<tr>
<td>Fox, Nathan</td>
<td>58</td>
</tr>
<tr>
<td>Franke, Barbara</td>
<td>19, 48, 49</td>
</tr>
<tr>
<td>Friedman, Lauren</td>
<td>58</td>
</tr>
<tr>
<td>Fried, Ronna</td>
<td>43, 56, 57, 63, 65</td>
</tr>
<tr>
<td>Froehlich, Tanya</td>
<td>24</td>
</tr>
<tr>
<td>Fuemmeler, Bernard</td>
<td>61</td>
</tr>
<tr>
<td>Gabrieli, John</td>
<td>20, 48, 62</td>
</tr>
<tr>
<td>Gaillard, Schuyler</td>
<td>62</td>
</tr>
<tr>
<td>Galdo, Maribel</td>
<td>57, 63</td>
</tr>
<tr>
<td>Gerhardt, Greg</td>
<td>61</td>
</tr>
<tr>
<td>Gibbons, Robert</td>
<td>67</td>
</tr>
<tr>
<td>Giedd, Jay</td>
<td>21, 44, 48</td>
</tr>
<tr>
<td>Glaser, Paul</td>
<td>40, 61</td>
</tr>
<tr>
<td>Author Name</td>
<td>Page(s)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Glatt, Stephen</td>
<td>62</td>
</tr>
<tr>
<td>Gnagy, Elizabeth</td>
<td>58</td>
</tr>
<tr>
<td>Goldman, Robert</td>
<td>67</td>
</tr>
<tr>
<td>Goldstein, Sam</td>
<td>24</td>
</tr>
<tr>
<td>Gomeni, Roberto</td>
<td>65</td>
</tr>
<tr>
<td>Goodman, David</td>
<td>24</td>
</tr>
<tr>
<td>Grace, Anthony</td>
<td>12, 33</td>
</tr>
<tr>
<td>Grizenko, Natalie</td>
<td>63</td>
</tr>
<tr>
<td>Grossman, Rebecca</td>
<td>66</td>
</tr>
<tr>
<td>Guenther, Sven</td>
<td>63</td>
</tr>
<tr>
<td>Hall, Anna</td>
<td>56</td>
</tr>
<tr>
<td>Hammerness, Paul</td>
<td>67</td>
</tr>
<tr>
<td>Handal, Nelson</td>
<td>67</td>
</tr>
<tr>
<td>Harty, Seth</td>
<td>64</td>
</tr>
<tr>
<td>Hegarty, Jani</td>
<td>55</td>
</tr>
<tr>
<td>Heiligenstein, John</td>
<td>24</td>
</tr>
<tr>
<td>Hernandez, Mariely</td>
<td>9</td>
</tr>
<tr>
<td>Hess, Jonathon</td>
<td>62</td>
</tr>
<tr>
<td>Hopkins, Seth</td>
<td>65, 67</td>
</tr>
<tr>
<td>Hoskova, Barbora</td>
<td>57, 63</td>
</tr>
<tr>
<td>Hsu, Jay</td>
<td>67</td>
</tr>
<tr>
<td>Huettl, Peter</td>
<td>61</td>
</tr>
<tr>
<td>Hung, Yuwen</td>
<td>62</td>
</tr>
<tr>
<td>Hur, Kwan</td>
<td>67</td>
</tr>
<tr>
<td>Iaccarino, Mary Alexis</td>
<td>57</td>
</tr>
<tr>
<td>Incledon, Beverly</td>
<td>60, 61, 65, 67</td>
</tr>
<tr>
<td>Isquith, Peter</td>
<td>65</td>
</tr>
<tr>
<td>Ivanov, Iliyan</td>
<td>57</td>
</tr>
<tr>
<td>Jacobs, Lisa</td>
<td>9</td>
</tr>
<tr>
<td>Jacobson, Lisa</td>
<td>57, 60</td>
</tr>
<tr>
<td>Jain, Rakesh</td>
<td>55</td>
</tr>
<tr>
<td>Jangmo, Andreas</td>
<td>40, 65</td>
</tr>
<tr>
<td>Jensen, Peter S.</td>
<td>60</td>
</tr>
<tr>
<td>Joobler, Ridha</td>
<td>63</td>
</tr>
<tr>
<td>Joseph, Heather</td>
<td>64</td>
</tr>
<tr>
<td>Joshi, Gagan</td>
<td>57, 59, 63</td>
</tr>
<tr>
<td>Kalb, Luke</td>
<td>60</td>
</tr>
<tr>
<td>Katzman, Martin</td>
<td>57, 58</td>
</tr>
<tr>
<td>Kelberman, Caroline</td>
<td>56, 62</td>
</tr>
<tr>
<td>Kennedy, Traci</td>
<td>9, 58</td>
</tr>
<tr>
<td>Khachatryan, Alexandra</td>
<td>60</td>
</tr>
<tr>
<td>Kim, Kristen</td>
<td>57</td>
</tr>
<tr>
<td>Kipp, Heidi</td>
<td>64</td>
</tr>
<tr>
<td>Koblan, Kenneth</td>
<td>65, 67</td>
</tr>
<tr>
<td>Kohn, Michael</td>
<td>62</td>
</tr>
<tr>
<td>Kollins, Scott</td>
<td>23, 41, 59, 60, 61, 64, 67</td>
</tr>
<tr>
<td>Author Name</td>
<td>Pages</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Nierenberg, Andrew</td>
<td>24, 51</td>
</tr>
<tr>
<td>Norman, Luke</td>
<td>9</td>
</tr>
<tr>
<td>Nullmeier, Rick</td>
<td>61</td>
</tr>
<tr>
<td>Nutt, Michael</td>
<td>63</td>
</tr>
<tr>
<td>O'Brien, Quentin</td>
<td>55</td>
</tr>
<tr>
<td>Otcheretko, Victor</td>
<td>63</td>
</tr>
<tr>
<td>Oyedele, Natasha</td>
<td>66</td>
</tr>
<tr>
<td>Pacelli, Sydney</td>
<td>62</td>
</tr>
<tr>
<td>Palumbo, Donna</td>
<td>55</td>
</tr>
<tr>
<td>Pardo, Antonio</td>
<td>64</td>
</tr>
<tr>
<td>Parvaz, Muhammad</td>
<td>57</td>
</tr>
<tr>
<td>Paterson, Andrew</td>
<td>61</td>
</tr>
<tr>
<td>Pearl, Amanda</td>
<td>60</td>
</tr>
<tr>
<td>Pedersen, Sarah</td>
<td>58</td>
</tr>
<tr>
<td>Pedraza, Juan</td>
<td>62</td>
</tr>
<tr>
<td>Pelham, William</td>
<td>58</td>
</tr>
<tr>
<td>Pennington, Bruce</td>
<td>61</td>
</tr>
<tr>
<td>Perlis, Roy</td>
<td>56</td>
</tr>
<tr>
<td>Pfiffler, Linda</td>
<td>58</td>
</tr>
<tr>
<td>Pikalov, Andrei</td>
<td>67</td>
</tr>
<tr>
<td>Pille, Rebecca O.</td>
<td>55</td>
</tr>
<tr>
<td>Pliszka, Steven</td>
<td>23, 49, 67</td>
</tr>
<tr>
<td>Pomerleau, Francois</td>
<td>61</td>
</tr>
<tr>
<td>Pope, Amanda</td>
<td>56</td>
</tr>
<tr>
<td>Posner, Jonathan</td>
<td>51</td>
</tr>
<tr>
<td>Pritchard, Alison</td>
<td>60</td>
</tr>
<tr>
<td>Pulii, Alexa</td>
<td>56, 57, 59</td>
</tr>
<tr>
<td>Quinn, Patrick</td>
<td>67</td>
</tr>
<tr>
<td>Ramaker, Sara</td>
<td>55</td>
</tr>
<tr>
<td>Ramsay, J. Russell</td>
<td>24, 43</td>
</tr>
<tr>
<td>Rhodewalt, Lauren</td>
<td>66</td>
</tr>
<tr>
<td>Robb, Adelaide</td>
<td>44</td>
</tr>
<tr>
<td>Robbins, Trevor</td>
<td>11, 33</td>
</tr>
<tr>
<td>Robertson, Brigitte</td>
<td>60, 63, 64</td>
</tr>
<tr>
<td>Rohde, Luis</td>
<td>23</td>
</tr>
<tr>
<td>Rostain, Anthony</td>
<td>23, 51</td>
</tr>
<tr>
<td>Roth, Robert</td>
<td>65</td>
</tr>
<tr>
<td>Roupe, Kathryn</td>
<td>63</td>
</tr>
<tr>
<td>Rubin, Jonathan</td>
<td>66</td>
</tr>
<tr>
<td>Saad, Jacqueline</td>
<td>40, 62</td>
</tr>
<tr>
<td>Saba, Victoria</td>
<td>61</td>
</tr>
<tr>
<td>Saito, Takuya</td>
<td>50</td>
</tr>
<tr>
<td>Sallee, F. Randy</td>
<td>60, 61, 65, 67</td>
</tr>
<tr>
<td>Saunders, Erika</td>
<td>60</td>
</tr>
<tr>
<td>Schachar, Russell</td>
<td>23, 39, 41, 61</td>
</tr>
<tr>
<td>Schaffer, Shane</td>
<td>66</td>
</tr>
<tr>
<td>Schechter, Julia</td>
<td>60, 61</td>
</tr>
<tr>
<td>Scherer, Steven</td>
<td>61</td>
</tr>
<tr>
<td>Schmith, Virginia</td>
<td>67</td>
</tr>
<tr>
<td>Schulz, Kurt</td>
<td>40, 62</td>
</tr>
<tr>
<td>Sergeant, Joseph</td>
<td>7, 35, 38</td>
</tr>
<tr>
<td>Shiflett, Michael</td>
<td>62</td>
</tr>
<tr>
<td>Shimko, Eitan</td>
<td>60</td>
</tr>
<tr>
<td>Sikes, Carolyn</td>
<td>66</td>
</tr>
<tr>
<td>Silva, Raul</td>
<td>66</td>
</tr>
<tr>
<td>Silverstein, Michael</td>
<td>56</td>
</tr>
<tr>
<td>Siner, David</td>
<td>66</td>
</tr>
<tr>
<td>Sleeper-Triplet, Jodi</td>
<td>52</td>
</tr>
<tr>
<td>Sloan, Jessica Solis</td>
<td>60</td>
</tr>
<tr>
<td>Smith, Adam</td>
<td>63</td>
</tr>
<tr>
<td>Smith, Katherine</td>
<td>55</td>
</tr>
<tr>
<td>Solanto, Mary</td>
<td>24</td>
</tr>
<tr>
<td>Soltanifar, Mohsen</td>
<td>61</td>
</tr>
<tr>
<td>Sonuga-Barke, Edmund</td>
<td>17, 47, 50</td>
</tr>
<tr>
<td>Soutullo, César</td>
<td>50</td>
</tr>
<tr>
<td>Spencer, Andrea</td>
<td>66</td>
</tr>
<tr>
<td>Spencer, Thomas</td>
<td>8, 24, 56, 57</td>
</tr>
<tr>
<td>Stacey, Engster</td>
<td>64</td>
</tr>
<tr>
<td>Stålhandske, Amanda</td>
<td>65</td>
</tr>
<tr>
<td>Stark, Jeffrey</td>
<td>66</td>
</tr>
<tr>
<td>Stein, Jeffrey</td>
<td>49</td>
</tr>
<tr>
<td>Stein, Mark</td>
<td>23, 37, 38, 42</td>
</tr>
<tr>
<td>Sternat, Tia</td>
<td>57, 58</td>
</tr>
<tr>
<td>Stevens, Howard</td>
<td>66</td>
</tr>
<tr>
<td>Stolper, Robert</td>
<td>60</td>
</tr>
<tr>
<td>Storch, Barbara</td>
<td>56</td>
</tr>
<tr>
<td>Straughn, Arthur</td>
<td>66</td>
</tr>
<tr>
<td>Stringaris, Argyris</td>
<td>51</td>
</tr>
<tr>
<td>Strug, Lisa</td>
<td>61</td>
</tr>
<tr>
<td>Sturm, Alexandra</td>
<td>65</td>
</tr>
<tr>
<td>Surman, Craig</td>
<td>24, 63, 66</td>
</tr>
<tr>
<td>Sweitzer, Maggie</td>
<td>60</td>
</tr>
<tr>
<td>Sykes, Carolyn R.</td>
<td>64</td>
</tr>
<tr>
<td>Taylor, Lea</td>
<td>55, 56, 57</td>
</tr>
<tr>
<td>Teuscher, Nathan</td>
<td>66</td>
</tr>
<tr>
<td>Thakkar, Vatsal</td>
<td>23</td>
</tr>
<tr>
<td>Thapar, Anita</td>
<td>16, 47</td>
</tr>
<tr>
<td>Tolbert, Sierra</td>
<td>61</td>
</tr>
<tr>
<td>Tsai, Joyce</td>
<td>67</td>
</tr>
<tr>
<td>Tuttle, Lisa</td>
<td>52</td>
</tr>
<tr>
<td>Uchida, Mai</td>
<td>56, 59, 62, 66</td>
</tr>
<tr>
<td>Vaudreuil, Carrie</td>
<td>66</td>
</tr>
<tr>
<td>Villodas, Miguel</td>
<td>58</td>
</tr>
<tr>
<td>Waite, Roberta</td>
<td>24, 60</td>
</tr>
<tr>
<td>Walther, Christine</td>
<td>58</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Waschbusch, Daniel 55, 60
Wasserstein, Jeanette 42
Waxmonsky, James 55, 60
Weiss, Margaret 24, 50
Wigal, Sharon 55, 67
Wigal, Tim 67
Wiggs, Kelsey 40, 67
Wilens, Timothy 13, 37, 44, 59, 60, 61, 67
Willcutt, Erik 61
Williams, Leanne 62
Wise, Barbara 59
Wolenski, Rebecca 59
Woodworth, Hilary 56
Woodworth, K. Yvonne 8, 56, 57, 59
Wozniak, Janet 44, 57, 59
Xiao, B. 61
Yan, Brian 64
Yu, Ming 64
Yule, Amy 39, 59, 63, 66
Zabel, T. Andrew 60
Zafonte, Ross 57
Zamora, Cynthia 63
Zarrei, Mehdi 61
Zhang-James, Yanli 62
Become an APSARD Member Today!

Visit www.APSARD.org for details!